

Binghamton University

The Open Repository @ Binghamton (The ORB)

Pharmacy Faculty Scholarship

School of Pharmacy and Pharmaceutical
Sciences

11-9-2023

Early life exposure to broccoli sprouts confers stronger protection against enterocolitis development in an immunological mouse model of inflammatory bowel disease

Lola Holcomb

Johanna M. Holman

Molly Hurd

Brigitte Lavoie

Louisa Colucci

See next page for additional authors

Follow this and additional works at: https://orb.binghamton.edu/pharmacy_fac



Part of the [Pharmacy and Pharmaceutical Sciences Commons](#)

Recommended Citation

Holcomb, Lola; Holman, Johanna M.; Hurd, Molly; Lavoie, Brigitte; Colucci, Louisa; Hunt, Benjamin; Hunt, Timothy; Kinney, Marissa; Pathak, Jahnavi; Mawe, Gary M.; Moses, Peter L.; Perry, Emma; Stratigakis, Allesandra; Zhang, Tao; Chen, Grace; Ishaq, Suzanne L.; and Li, Yanyan, "Early life exposure to broccoli sprouts confers stronger protection against enterocolitis development in an immunological mouse model of inflammatory bowel disease" (2023). *Pharmacy Faculty Scholarship*. 6.
https://orb.binghamton.edu/pharmacy_fac/6

This Article is brought to you for free and open access by the School of Pharmacy and Pharmaceutical Sciences at The Open Repository @ Binghamton (The ORB). It has been accepted for inclusion in Pharmacy Faculty Scholarship by an authorized administrator of The Open Repository @ Binghamton (The ORB). For more information, please contact ORB@binghamton.edu.

Authors

Lola Holcomb, Johanna M. Holman, Molly Hurd, Brigitte Lavoie, Louisa Colucci, Benjamin Hunt, Timothy Hunt, Marissa Kinney, Jahnavi Pathak, Gary M. Mawe, Peter L. Moses, Emma Perry, Allesandra Stratigakis, Tao Zhang, Grace Chen, Suzanne L. Ishaq, and Yanyan Li

Early life exposure to broccoli sprouts confers stronger protection against enterocolitis development in an immunological mouse model of inflammatory bowel disease

Lola Holcomb,¹ Johanna M. Holman,² Molly Hurd,³ Brigitte Lavoie,³ Louisa Colucci,⁴ Benjamin Hunt,⁵ Timothy Hunt,⁵ Marissa Kinney,² Jahnvi Pathak,¹ Gary M. Mawe,³ Peter L. Moses,^{3,6} Emma Perry,⁷ Allesandra Stratigakis,⁸ Tao Zhang,⁸ Grace Chen,⁹ Suzanne L. Ishaq,¹ Yanyan Li¹

AUTHOR AFFILIATIONS See affiliation list on p. 23.

ABSTRACT Crohn's disease (CD) is a presentation of inflammatory bowel disease (IBD) that manifests in childhood and adolescence and involves chronic and severe enterocolitis, immune and gut microbial dysregulation, and other complications. Diet and gut-microbiota-produced metabolites are sources of anti-inflammatories that could ameliorate symptoms. However, questions remain on how IBD influences biogeographic patterns of microbial location and function in the gut, how early life transitional gut communities are affected by IBD and diet interventions, and how disruption to biogeography alters disease mediation by diet components or microbial metabolites. Many studies on diet and IBD use a chemically induced ulcerative colitis model, despite the availability of an immune-modulated CD model. Interleukin-10-knockout (IL-10-KO) mice on a C57BL/6 background, beginning at age 4 or 7 weeks, were fed a control diet or one containing 10% (wt/wt) raw broccoli sprouts, which was high in the sprout-sourced anti-inflammatory sulforaphane. Diets began 7 days prior to, and for 2 weeks after inoculation with *Helicobacter hepaticus*, which triggers Crohn's-like symptoms in these immune-impaired mice. The broccoli sprout diet increased sulforaphane in plasma; decreased weight stagnation, fecal blood, and diarrhea associated; and increased microbiota richness in the gut, especially in younger mice. Sprout diets resulted in some anatomically specific bacteria in younger mice and reduced the prevalence and abundance of pathobiont bacteria which trigger inflammation in the IL-10-KO mouse, for example, *Escherichia coli* and *Helicobacter*. Overall, the IL-10-KO mouse model is responsive to a raw broccoli sprout diet and represents an opportunity for more diet-host-microbiome research.

IMPORTANCE To our knowledge, IL-10-KO mice have not previously been used to investigate the interactions of host, microbiota, and broccoli, broccoli sprouts, or broccoli bioactives in resolving symptoms of CD. We showed that a diet containing 10% raw broccoli sprouts increased the plasma concentration of the anti-inflammatory compound sulforaphane and protected mice to varying degrees against disease symptoms, including weight loss or stagnation, fecal blood, and diarrhea. Younger mice responded more strongly to the diet, further reducing symptoms, as well as increased gut bacterial richness, increased bacterial community similarity to each other, and more location-specific communities than older mice on the diet intervention. Crohn's disease disrupts the lives of patients and requires people to alter dietary and lifestyle habits to manage symptoms. The current medical treatment is expensive with significant side effects, and a dietary intervention represents an affordable, accessible, and simple strategy to reduce the burden of symptoms.

Editor Hiutung Chu, University of California, San Diego, La Jolla, California, USA

Address correspondence to Suzanne L. Ishaq, sue.ishaq@maine.edu, or Yanyan Li, yanyan.li@maine.edu.

Lola Holcomb and Johanna M. Holman contributed equally to this article. Author order was determined by amount of data analysis and interpretation provided.

The authors declare no conflict of interest.

See the funding table on p. 23.

Received 21 July 2023

Accepted 2 October 2023

Published 9 November 2023

Copyright © 2023 Holcomb et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

KEYWORDS Crohn's disease, cruciferous vegetables, sulforaphane, glucoraphanin, gut microbiota, dietary bioactives, 16S rDNA, interleukin-10 knockout

Inflammatory bowel diseases (IBD) affect over 6 million people globally, with more than 25% of cases reported in the United States (1). The varied combination of symptoms, the intensity of presentation, and the multifactorial origin make it difficult (2) and expensive for patients to manage (3) and detract from the quality of life (4, 5). Crohn's disease (CD) is one of the primary immune-disordered presentations of IBD, and currently available treatments attempt to suppress the immune response to alleviate inflammation and to return patients to as close to homeostasis as possible; however, many patients (6) respond poorly. Diet can play an important, economical, and accessible role in the prevention and/or management of IBD as a source of anti-inflammatory metabolites (7, 8), and broadly for influencing the robustness of the gut microbiome (9–11). However, there are gaps in knowledge about how IBD affects gut microbial ecology, including taxonomic and metabolic biogeography (12–14), how gut microbiota mediate response to disease (15) or diet (16, 17), and how dietary components and microbial metabolites improve symptoms (18, 19).

Inflammation in CD is severe and disrupts host-microbial interactions

Inflammation in CD is chronic, relapsing, occurs throughout the gastrointestinal (GI) tract and involves several breakdowns of the innate immune system (20, 21). Decreased expression of the MUC1 gene reduces coverage of mucin in the ileum (22) and tight junction proteins (23), allowing microbial translocation from the gut to other tissues (20, 21). In addition, poor absorption of bile salts in the ileum causes damage to the colon (24). CD patients mount weak acute inflammation and low neutrophil counts in response to infection (20) and may be unable to clear infections. This results in infiltration of fecal material through the mucosal lining of the gut, dysregulation of the adaptive immune response, and results in chronic inflammation (20, 25). The adaptive immune response in CD primarily involves excessive recruitment of effector T cells (Th1 and Th17) by inflammatory cytokines (interleukin-12, -18, and -23) which are upregulated in CD lesions (26–28). The duration of inflammation, damage to intestinal walls, and other negative outcomes associated with CD increase the risk of developing GI cancers, such as colorectal cancer (29).

CD disrupts microbial community development from adolescence to early adulthood

CD typically presents during late adolescence and early adulthood (6), between the ages of 15 and 30, and approximately 20%–30% of cases occur in children and adolescents under the age of 18 (27, 30). Children and adolescents diagnosed with CD encounter distinct challenges, as their gut microbiome is disrupted during critical periods of anatomical, immunological, and microbiological development (31–33). The composition of the gut microbiota changes from transitional microbial communities in childhood to a more stable community in adulthood (10), with distinct variations in the composition of gut microbiota between people who are healthy or have CD. For example, pediatric patients exhibit decreased bacterial α -diversity and β -diversity compared to healthy children (31–33), and while no specific gut microbiota alterations were consistently reported, a gain in *Enterococcus* and a significant decrease in *Anaerostipes*, *Blautia*, *Coprococcus*, *Faecalibacterium*, *Roseburia*, *Ruminococcus*, and *Lachnospira* have been noted (31–33). There are also variations across different age groups with CD, from infants through elderly patients (34–36). Older patients tend to exhibit a higher prevalence of colitis, whereas younger patients are more likely to present with ileal disease (37), which may result in age-specific and location-specific changes to gut microbiota. A more thorough understanding of microbial location in the gut (biogeography) may provide more insight into the interactions between host and microbiota in the development of CD.

Diet can be a source of anti-inflammatories to complement medical strategies

Diets that are high in cruciferous vegetables may reduce GI inflammation and cancer risk (8, 38), in part because these vegetables contain sulfur-containing glucosinolates (GSLs) that can be metabolized to beneficial compounds (39, 40). However, CD patients have historically been advised to avoid cruciferous vegetables (41) and sulfur-rich diets (42). Isothiocyanates (ITCs) are a class of bioactive compounds derived from GSLs, which can reduce inflammation including in IBD patients (8, 40, 43). Sulforaphane (SFN), the most well-studied ITC, is produced from the GSL glucoraphanin (GLR), inhibits the immune factor NF- κ B, and downregulates multiple inflammatory pathways *ex vivo* and *in vivo* (8, 43–46).

Purified GLR or SFN has been demonstrated to protect against chemical-induced ulcerative colitis in mice (38, 47–49) and some pathogenic bacteria in the gut (50, 51). However, purified SFN is unstable (52, 53), and pure GLR induces extremely variable rates of conversion in humans (40, 53). The conversion of GLR to SFN is achieved by plant-sourced enzymes when raw vegetables are chewed or chopped, as well as by microbially sourced enzymes in the gut (38, 48, 51). GLR is concentrated in broccoli sprouts, and our data have shown that a whole-food strategy using sprouts increases gut microbial richness, raises SFN levels in colon tissues and plasma, and reduces inflammation in chemically induced models of colitis (38, 47, 48).

Diet studies using immunological models of IBD are lacking

The interleukin (IL) 10 knockout (IL-10-KO) mouse is commonly used as a genetic model well-suited to studying the immune factors, inflammation, and microbiota of CD (54, 55). IL-10 stimulates the growth and differentiation of numerous cell types, suppresses macrophage activation, inhibits inflammatory cytokine production, displays multiple mechanisms of control of Th1 cells (56), and modulates the innate immune response to microorganisms (57). IL-10-KO mice are raised in pathogen-free conditions and develop chronic enterocolitis upon exposure to microorganisms that act commensally in immune-competent mice, and their response resembles the transmural inflammation of CD, complete with the formation of granulomas, crypt abscesses, mucosal hyperplasia, as well as aberrant immune cell response (58, 59).

To our knowledge, IL-10-KO mice have not been used to investigate the interactions of host, microbiota, and broccoli, broccoli sprouts, or related bioactives in reducing inflammation, modifying the immune response, and supporting GI microbial systems. The objective of this study was to evaluate IL-10-KO mice as a model for studying the broccoli sprout bioactives. We hypothesized that 10% (wt/wt) of raw broccoli sprouts in the diet, which contains both the GLR precursor and the anti-inflammatory byproduct SFN, would protect mice from inflammation triggered by microbial conventionalization even in a host with disrupted responses to commensal bacteria. We hypothesized that sprouts would alter the gut microbiota and in location-specific patterns, and increase the abundance of potentially beneficial taxa while reducing the abundance of putative pathogens.

It is standard to conventionalize IL-10-KO at approximately 8 weeks of age (60), to mimic typical timing for the onset of symptoms. In conducting two replications of a diet trial, we used mice beginning the diet at 4 weeks (~1 week after weaning [(61)]) and 7 weeks of age, and conventionalized at 5 and 8 weeks, respectively. We observed a previously unreported effect of young age on the effectiveness of adding broccoli sprouts in the diet to reduce symptoms of enterocolitis and added an *a posteriori* hypothesis that younger mice with transitional gut microbial communities might be more amenable to changes from this diet (61, 62).

RESULTS

Raw broccoli sprouts alleviated disease characteristics of immune-modulated enterocolitis

The experimental design was structured as a prevention paradigm (Fig. 1) in which specific-pathogen-free, homozygous IL-10-KO mice were given *ad libitum* either a standard chow diet (5LOD irradiated) or the treatment diet consisting of 10% (wt/wt) raw broccoli sprouts, which were balanced for micronutrients and macronutrients including fibers. Mice began the diet at 4 weeks (1 week after weaning [61]) and 7 weeks of age and continued for an additional 16 days during the disease induction via microbial colonization/conventionalization and symptom onset. Raw broccoli sprouts contain concentrated amounts of GLR, some of which is metabolized to SFN by mastication or diet preparation when the broccoli enzyme myrosinase is released from tissues (63). The control diet contained no GLR or SFN, and the broccoli sprout diet contained on average 4 μg of GLR and 85 μg of SFN per gram of diet sampled.

Trial 1 included 9 mice ($n = 5$ in the treatment group and 4 in the control group) starting the diet at 4 weeks of age, and conventionalized at 5 weeks. Trial 2 included 11 mice ($n = 5$ in the treatment group and 6 in the control group) starting the diet at 7 weeks of age, and conventionalized at 8 weeks which is the standard age for inducing symptoms in IL-10-KO mice. The younger mice consuming the broccoli sprout diet continued to gain weight once enterocolitis was induced compared to their baseline weight, and the younger mice fed the control diet plateaued around 120% of body weight (Fig. 2A, ANOVA $P < 0.001$). The older mice had a similar weight stagnation during enterocolitis regardless of diet (Fig. 2B).




FIG 1 Experimental design for a dietary prevention model of Crohn's disease in interleukin-10 knockout mice beginning at age 4 or 7 weeks. Mice were raised in a barrier facility and fed a control or 10% raw broccoli sprout diet for 7 days, then for an additional 16 days as they were moved to a conventional room and co-housed with a *Helicobacter hepaticus*-positive mouse to induce immune-mediated enterocolitis.




FIG 2 A 10% raw broccoli sprout diet significantly attenuated the development of colitis in IL-10-KO mice that were (A) 4–6 weeks old during the trial or (B) 7–9 weeks old during the trial. Brown lines indicate the control diet ($n = 4$, trial 1; $n = 6$, trial 2) and green lines indicate a sprout diet ($n = 5$, trial 1; $n = 5$, trial 2). All mice were in a growth phase, so body weights and time scales were normalized to the day mice were exposed to *H. hepaticus*-positive mice, set at 100% starting weight and day 0, respectively. Disease activity index scores are calculated by weight loss intensity score, fecal blood, and fecal consistency. Overall model significance is included on the chart, and single timepoint comparisons and significance was designated as $P < 0.05$; $**P < 0.01$; $***P < 0.001$; $****P < 0.0001$ by two-way ANOVA, and post multiple comparisons by Sidak.

Consumption of the broccoli diet significantly attenuated the disease development regardless of age group, as indicated by lower disease activity index (DAI) scores (Fig. 2, ANOVA $P < 0.001$). DAI scores were calculated based on three characteristics: fecal blood (presence/absence), fecal blood severity, and fecal consistency (firm/loose/diarrhea). The higher the DAI score, the more severe the disease was.

Lipocalin (LCN2), a neutrophil protein that binds bacterial siderophores, serves as a biomarker for intestinal inflammation (64). Analysis of fecal samples from both age groups on the day of microbial exposure for conventionalization (D0), appearance of symptoms (D10), and end of the trial (D15/16) revealed a markedly lower LCN2 concentration in the group of mice fed the 10% raw broccoli sprouts diet compared to the control diet at both D10 and D15/16 (Fig. 3A; ANOVA, $P < 0.05$). This was confirmed by serum lipocalin on D15/16, which showed a marked decrease in LCN2 concentration in the group of mice fed the 10% raw broccoli sprouts diet compared to the control




FIG 3 Levels of fecal lipocalin for (A) younger and (B) older mice, serum cytokines in (C) younger and (D) older mice, (E) plasma lipocalin, and (F) plasma sulforaphane, in IL-10-KO mice with enterocolitis while consuming 10% (wt/wt) raw broccoli sprouts or control diets. Stool samples were collected from mice ($n = 10$ /group across both trials) on days 0 (conventionalization), 10 (onset of symptoms), and 15/16 of experiment for lipocalin-2 (Lpn/Lcn) concentration determination. Plasma was collected on day 15/16 for lipocalin, cytokines, and sulforaphane concentration. For fecal lipocalin, data were normalized by the weight of feces, and significance was set as $*P < 0.05$.

diet (Fig. 3B, ANOVA $P < 0.05$). Similarly, on D15/16, pro-inflammatory cytokines IL-6 and TNF- α were significantly reduced in the plasma of younger mice consuming broccoli sprouts (Fig. 3C; ANOVA, $P < 0.05$), but not reduced in older mice (Fig. 3D).

SFN was absorbed from the gut by the mice consuming broccoli sprouts in both age groups and was found in high concentrations in their plasma, while control mice exhibited no circulating SFN (Fig. 3E; ANOVA $P < 0.05$).

Tissues from the ileum, proximal colon, and distal colon were collected for histological scoring (0 = no signs, to 2 = significant signs) of epithelial damage, architectural changes, infiltration of mononuclear cells into the lamina propria, infiltration of polymorphonuclear cells in the lamina propria or into the epithelium, as well as abscesses, ulcers, erosion, and branched crypts which were scored together (Fig. S1). Diet was not a significant factor for most scoring criteria, even when data were subset by trial/age, or subset by organ. The exception to this was the infiltration of mononuclear cells into the lamina propria, which was significantly lower (linear regression model (lm), $P = 0.02$) in the younger broccoli sprout mice compared to control mice in trial 1.

Age significantly influenced bacterial community responsiveness to raw broccoli sprouts

Of the three experimental factors analyzed in this study, we report that age is the most significant factor (relative to diet and anatomical location) in driving the richness of gut bacterial communities, as well as their similarity to each other. The younger trial 1 mice that started consuming the raw broccoli sprouts at 4 weeks of age had greater observed bacterial richness by 6 weeks of age than their counterparts fed a control diet (Fig. 4A; permutational analysis of variance [perMANOVA], $P < 0.05$). However, mice in trial 2, starting at 7 weeks, showed no significant difference in bacterial richness compared to their control group by age 9 weeks (Fig. 4B; perMANOVA, $P > 0.05$). When comparing bacterial communities within each age group and within each of the four anatomical locations studied, the broccoli sprout diet increased bacterial richness in the cecum and the proximal colon of the younger mice, compared to the younger controls (Fig. 4B; Wilcoxon tests, $P < 0.05$). There was no difference between bacterial richness in any gut location in the older mice consuming broccoli sprouts versus the control diet.

When comparing bacterial community similarity between all samples (beta diversity), age was again the strongest explanatory factor when comparing bacterial taxa presence/absence (unweighted, Fig. S2 and S3) and presence and abundance (weighted, Fig. 5 and 6) metrics. Within the younger trial 1 group, bacterial communities clustered separately by diet (Fig. 5; Table 1; perMANOVA, $P < 0.001$). This was, in part, due to significant taxonomic dissimilarity between the two diet groups in the cecum and the distal colon (Fig. 6; Table 1), while differences between diet groups within the proximal colon were approaching significance. Within the older trial 2 mice, diet was also the most significant driver of bacterial community similarity, but to a lesser extent than in the younger mice (Fig. 5; Table 1; perMANOVA: lower F values, $P < 0.03$). Overall, anatomical location was a significant factor in bacterial community similarity in older mice; however, within each of the four anatomical locations studied, there was no significant effect between the diets ($P > 0.05$), indicating smaller-scale changes across the GI tract communities.

The bacterial taxa that drove the differences between age, diet, and anatomical treatment were primarily different sequence variants (SVs) identified to the Muribaculaceae and Lachnospiraceae families, common mouse commensals, abundant in younger broccoli sprout-fed mice (Fig. S4). The lactic acid-fermenting genus *Limosilactobacillus* was found in older mice and was more abundant in older mice consuming broccoli sprouts (Fig. S4). *Helicobacter typhlonius*, which is pathogenic in immunocompromised mice, was abundant in control mice of both ages and in older mice consuming sprouts, while *Escherichia* was found in many locations in the control mice but only a few older mice consuming sprouts (Fig. S4).




FIG 4 Observed bacterial richness within the gastrointestinal tracts of IL-10-KO mice fed control diets or raw broccoli sprout diets from 4 to 6 weeks of age (trial 1) and 7–9 weeks of age (trial 2). Panel A shows comparison of broccoli-fed and control mice in trial 1 and trial 2 mice across the whole gastrointestinal tract ($***P < 0.001$); panel B shows the comparisons of broccoli-fed and control mice which were 4–6 weeks old for the duration of the first trial and 7–9 weeks old in the second trial, in each anatomical location scraping site ($*P < 0.05$). Graphics made using phyloseq and ggplot2 packages in R. Significance added by Wilcox tests from the ggsignif package in R.

Bacterial taxa which were abundant in more than 70% of samples in the groups subset by trial/age and diet were considered part of the “core” community. SVs in the Muribaculaceae family made up much of the core microbiota specific to each group, as well as several SVs identified to Lachnospiraceae, *Bacteroidetes*, *Helicobacter*, and others (Fig. S5). *Helicobacter* was more prevalent and abundant in control mice of both ages.

The Source Tracker algorithm was used to determine whether the cecum could be the “source” for bacterial population “sinks” in the colon, as a proxy for the mouse model’s




FIG 5 Principal coordinate analysis of bacterial community similarity within the gastrointestinal tracts of 4- or 7-week-old IL-10-KO mice fed control diets or broccoli sprout diets. Calculations using weighted Bray-Curtis dissimilarity show differences in the taxonomic structure of trial 1 mice in panel A and trial 2 mice in panel B. Graphic made using phyloseq, and vegan packages in R.

TABLE 1 Statistical comparison of principal coordinate analysis of bacterial community similarity within the gastrointestinal tracts of 4- or 7-week-old IL-10-KO mice fed control diets or broccoli sprout diets^a

Permanova tests of dissimilarity	Df	Test type ^e	Trial 1, aged 4–6 weeks		Trial 2, aged 7–9 weeks	
			F	P-value	F	P-value
Diet	1	Jac	2.7779	0.0001 ^b	1.1898	0.0258 ^d
		BC	7.5867	0.0001 ^b	2.4498	0.0022 ^c
Anatomical location	3	Jac	1.2027	0.0291 ^d	1.0955	0.0359 ^d
		BC	1.5991	0.0205 ^d	1.4958	0.0139 ^d
Diet: anatomical location	3	Jac	1.0704	0.1780	0.9559	0.8477
		BC	1.0482	0.3504	0.8272	0.8300
Diet effect within the ileum	1	Jac	1.1319	0.1242	1.0154	0.3133
		BC	1.4445	0.1220	1.3366	0.1699
Diet effect within the cecum	1	Jac	1.9352	0.0074 ^c	1.0393	0.2663
		BC	4.4036	0.0081 ^c	1.6667	0.0818
Diet effect within the proximal colon	1	Jac	1.3499	0.0554	0.9949	0.3998
		BC	2.0148	0.0247 ^d	0.8776	0.6080
Diet effect within the distal colon	1	Jac	1.7018	0.0261 ^d	1.0058	0.4183
		BC	4.1923	0.0158 ^d	0.9797	0.4679

^aComparisons were done using dietary treatment and anatomical locations as factors, and subsetting by trial, as well as by anatomical location, as noted. Unweighted Jaccard similarity and weighted Bray-Curtis metrics were used to calculate beta diversity. Number of permutations = 9,999.

^bP ≤ 0.001.

^cP ≤ 0.01.

^dP ≤ 0.05.

^eJaccard dissimilarity = "Jac" | Bray-Curtis dissimilarity = "BC".




FIG 6 Bacterial community dissimilarity within a specific anatomical location along the gastrointestinal tract of IL-10-KO mice fed control diets or broccoli sprout diets beginning at 4 or 7 weeks of age. Calculations using weighted Bray-Curtis dissimilarity show differences in the taxonomic structure of (A) trial 1 mice sampled at age 6 weeks and (B) trial 2 mice sampled at age 9 weeks, after each had been consuming diets for 3 weeks. Principal coordinate analysis graphic made using phyloseq, and vegan packages in R.

applicability to the human gut anatomical features and microbial communities. A total of 38 SVs were identified as possibly sourced from the cecum (Fig. S6). Common mouse commensals, but not the putative GSL-converting bacteria in the broccoli sprout-fed gut samples, were among those taxa identified as sourced in the cecum and sinking in the proximal or distal colon.

Raw broccoli sprout diet reduced the abundance of putative pathogens

SFN is bacteriostatic against common gut pathogens, including *Escherichia coli*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, *S. epidermidis*, *Enterococcus faecalis*, *Bacillus cereus* as well as non-pathogenic *Bacillus*, and *Helicobacter* spp., which can be commensal in immune-competent mice (50, 65). Using the previous literature, we quantified differences in abundance in putative pathogens, which were higher in control groups, across more locations in the gut, and in higher abundance than the broccoli sprout groups (Fig. 7). This trend was more pronounced in older control mice which exhibited an abundance of *Helicobacter* SVs through the cecum, proximal colon, and distal colon, as compared to the younger controls (Fig. 7; ANOVA, $P = 0.147$). Within the broccoli sprout groups, the older mice also appeared to have a greater abundance of *Helicobacter* SVs compared to their younger counterparts in the distal colon, although it was not statistically significant (Fig. 7; ANOVA, $P = 0.657$).




FIG 7 Bacterial SVs of genera that have putative pathogenicity. Trial 1 (left): 36 gut samples and 107 SVs; trial 2 (right): 39 gut samples and 103 SVs. Graphic made using phyloseq and ggplot2 packages in R.

Raw broccoli sprout diet increased certain putative GLR metabolizing taxa

Several bacterial taxa perform myrosinase-like enzymatic activity and metabolize GLR into SFN, and after consulting the current literature, we identified 19 taxa to analyze in detail (38, 66, 67). From our samples, we identified 562 SVs belonging to the following genera: *Bacillus*, *Bacteroides*, *Enterococcus*, *Lactobacillus*, *Lactococcus*, *Pseudomonas*, and *Staphylococcus* (Fig. 8). Although we did not find *Bifidobacterium*, *Listeria*, *Pediococcus*, *Streptomyces*, *Aerobacter*, *Citrobacter*, *Enterobacter*, *Escherichia*, *Salmonella*, *Paracolobactrum*, *Proteus*, or *Faecalibacterium*. There were few previously identified putative GSL-converting taxa found in the younger mice fed the broccoli sprout diet; however, there were higher read counts for *Bacteroides* and *Lactobacillus* in the younger controls as compared with older controls or broccoli-fed groups (Fig. 8; ANOVA, $P < 0.01$). Both diet groups of older mice exhibited high read counts of *Bacillus* and *Enterococcus* SVs (Fig. 8).

The reads from putative GSL-converting genera were identified at species level using NCBI BLASTN (Fig. 9). The younger mice consuming sprouts contained *Bacteroides sartorii* and *B. acidifaciens* in the cecum and distal colon, and *B. caecimuris*, *B. sartorii*, and *B. acidifaciens* in the proximal colon. Most of the SVs in the ileum could not be identified at the species level. In the older trial, similar GSL-converting taxa were present, with five of the identified species having high abundance (Fig. 9). The older sprout-fed mice contained many *Lactobacillus intestinalis* reads in the ileum, with fewer in the cecum, proximal and distal colon; many *B. caecimuris* and *B. acidifaciens* reads in the cecum, and proximal and distal colon; and *B. sartorii* in the proximal and distal colon.

By contrast, the younger control group had four of the identified GSL-converting species (Fig. 9): *Lactobacillus gasseri* in the ileum, proximal and distal colon; *B. sartorii*, *B.*




FIG 8 Read counts of bacterial SVs of genera that have the putative capacity to convert glucoraphanin to sulforaphane (GSL). Strains of bacteria in these genera have been demonstrated to perform myrosinase-like activity in the digestive tract, as reviewed in reference 68. Trial 1 (left): 36 gut samples and 241 SVs; trial 2 (right): 39 gut samples and 353 SVs. Graphic made using phyloseq and ggplot2 packages in R.

caecimuris, and *B. acidifaciens* in the cecum, proximal and distal colon). The older control group also had abundant *L. gasseri* in the ileum, but much less in the proximal and distal colon; *B. acidifaciens* was dominant in the cecum, proximal and distal colon; *L. intestinalis* was present in the ileum, cecum, and distal colon; and *B. sartorii* was abundant in cecum, proximal and distal colon (Fig. 9). The older control mice had a minor abundance of *E. casseliflavus*, *E. faecalis*, *B. thetaiotaomicron*, *E. cecorum*, and *S. aureus* (data not shown).

The presence of *Bacteroides thetaiotaomicron* (*B. theta*) was further investigated through quantitative polymerase chain reaction (qPCR) amplification of its SusR4 regulon, which contains the BT2159-BT2156 operon and the regulatory gene BT2160, from samples along the digestive tract (ileum, cecum, and proximal and distal colon) of mice consuming broccoli sprout and control diets. For *B. theta*, this operon has been demonstrated as necessary and sufficient for GSL metabolism and ITC production both *in vivo* and *in vitro* (69). These genes code for enzymes (a sugar phosphate isomerase, glycosyl hydrolase, and two oxidoreductases) that support the transformation of GLR to the bioactive SFN. We found copies of *B. theta* genes BT2156 in the ileum, cecum, and distal colon, with a small number of copies in the proximal colon (Fig. S7). BT2159 had some copies in the cecum in both diet cohorts of mice, with other gene copies present in low quantities across diet and anatomical location. The highest copy number of any gene, and the only significant comparison by diet, was BT2156 in the distal colon of broccoli sprout-fed mice (ANOVA, difference = 92,362 gene copies more than control mice, $P = 0.00499$, controlling for trial).

Liou et al. found that SFN production by *B. theta* required BT2158 together with either BT2156 or BT2157 but was most effective when all four operon genes acted in concert (69). Thus, at each anatomical location, we characterized the distribution of the presence




FIG 9 Biogeographic frequency of species from putative GSL-converting genera in the treatment groups. The Silva Database identified *Bacteroides* species *acidifaciens*, *caecimuris*, and *sartorii*, *Enterococcus cecorum*, *Staphylococcus aureus*, and *Lactobacillus intestinalis*. NCBI BLASTN identified additional *B. acidifaciens*, *B. caecimuris*, and *B. sartorii*. BLASTN uniquely identified *Enterococcus* species *casseliflavus* and *faecalis*, and *Lactobacillus gasseri*. *Bacteroides thetaiotaomicron* was linked to two (2) SVs based on genome mapping. *E. cecorum* (frequency 12), *S. aureus* (2), and *B. thetaiotaomicron* (5) were not included in the figure as their frequencies were minimal.

of the operon genes (Fig. 10A). In younger mice, the sprouts diet increased the presence of the operon in all locations but especially the distal colon where 100% of younger mice had high abundance (max operon mean copy count >10,000; Fig. 10A). For the young mice (trial 1) across all anatomical sites, we found that the broccoli diet on average shifted the proportion of mice with a high operon indication (max operon mean copy count >10,000) from 24% in controls to 64% in the treatment group (Fig. 10B). For the older mice (trial 2), the impact of the broccoli diet was not as evident between treatment and control group (Fig. 10B), although in broccoli sprout fed mice showed medium high abundance and prevalence in all gut locations and high in the distal colon (Fig. 10A).



DISCUSSION

IL-10-KO is an effective model for evaluating host, diet, immune response, and microbiota

This pilot study evaluated IL-10-KO mice as a model for using dietary broccoli sprout bioactives to reduce inflammation, modify the immune response, and support GI tract microbiota. Inflammatory diseases such as CD are associated with changes in the presence, abundance, and functionality of the microbiome (34, 35, 70), and therapies that improve the gut microbiome have the potential to alleviate symptoms (47, 71). Specific pathogen-free IL-10-KO mice acquire gut microbiota as they age (72), but they never fully develop diverse, commensal microbiota and this appears to be attributable to the spontaneous generation of enterocolitis at the 4–6 weeks of age (73). Diet is an important driver of microbiota development in early life (10), and the wealth of microbial byproducts from fiber-rich foods is demonstrated to recruit and maintain a diverse microbial community (74, 75), reduce inflammation, improve nutrition, and stimulate gut motility —aspects which are limited in IBD (34, 76, 77). In our study, raw broccoli sprouts

A

C57BL/6 IL10 – Helicobacter



B

High Operon Indication (> 10,000) - Average Across All Anatomical Sites




FIG 10 Prevalence of the operon BT2159-BT2156 in *Bacteroides thetaiotaomicron* (VPI-5482) in 4- to 6 week-old (trial 1) and 7- to 9 week-old (trial 2) IL-10-KO mice fed either a control or raw broccoli sprout diet. (A) Percentages indicate the number of samples with a max operon mean copy count in each category (red low < 100, purple medium 100–10,000, blue high > 10,000). (B) Average high indication across all anatomical sites by trial and diet.

provided during the critical period of microbial community stabilization and enterocolitis development in these IL-10-KO mice resulted in an increase in microbial diversity, increased abundance of potentially beneficial bacteria, and a reduction of potentially pathogenic bacteria. We did not see an improvement in histological damage, which may have been precluded by the use of raw sprouts, as feeding pure SFN results in high absorption in the stomach which decreases over the GI tract (78).

Dextran sodium sulfate (DSS)-induced colitis is an established animal model for studying IBD (47, 79, 80), which has a disease profile similar in progression and morphology to human ulcerative colitis (79, 81). DSS modifies the expression of tight junction proteins in intestinal epithelial cells, leading to a leaky epithelial barrier (82), goblet cell depletion, erosion, ulceration, and infiltration of neutrophils into the lamina propria and submucosa (83), triggering the innate immune response (84, 85) but circumventing the canonical inflammatory pathway (86). As DSS instigates colitis through chemical and physical damage, without a direct interaction with the immune system, it is inadequate for investigating the specific immunohistopathology present in CD. While a few studies have used IL-10-KO mice to study the effects of certain mineral additives (66, 87), isomaltodextrin supplementation (67), or high-fat diets on colitis (88, 89), the use of this model for diet studies is still nascent. We demonstrated that 10% raw broccoli sprouts in the diet of IL-10-KO mice induced increased bacterial richness, SFN in the plasma, and collectively reduced the symptoms of enterocolitis.

Younger IL-10-KO mice were more responsive to dietary intervention

We observed a previously unreported effect of age in early life—a three-week difference—on the heightened response of younger mice to broccoli sprouts, and we hypothesized that this was driven by the instability of the developing gut microbiota and its amenability to selective pressures in younger mice (61, 90, 91). Mice wean at approximately 20–22 days of life (3 weeks) which is a critical period for the co-development of the immune system and gut microbiota, and is coordinated by immune factors in milk, growth of the GI tract, and improvement of epithelial barrier function (92). By 28–35 days of life (4–5 weeks), juvenile mice begin sexual development and still have a changing gut microbial community (93). By days 35–42 (5–6 weeks), they begin adolescence (94) during which their gut community stabilizes unless it is perturbed (93). Thus, our younger mice were still in a transitional state of life and older mice were just beginning a period of life marked by stability of the immune system and gut microbial communities. Our findings are consistent with previous human studies that suggest that the gut microbiota of infants and children are more plastic than that of adults (10): starting around age 3, gut microbiota fall into long-term patterns driven by consistency in diet and lifestyle (10, 74, 95, 96). Collectively, this may indicate that dietary interventions to restructure the microbiota would be more effective in children and adolescents than in adults, which is supported by other literature (71).

Furthermore, compared to the controls, the younger mice fed a diet containing broccoli sprouts had more bacterial genera to meet the *ad hoc* core cutoff for prevalence and abundance. The gut microbiome of pediatric CD patients shows divergence from healthy siblings early in the disease and a more definable “disease state microbiome” than adults with CD (31–33). We found that the older broccoli-fed mice had fewer genera that met the core standard, which could suggest that the core gut microbial community diminishes with age and interventions would need to be individualized. In adults, undergoing dietary change is one of the few external factors that can “destabilize,” or subject the adult gut microbiota to change (10, 96), which may be useful in removing gut microbial communities that are not providing functional benefits and recruiting a different community instead.

Biogeographic patterns emergent in younger mice consuming broccoli sprouts

Anatomical location within the gut, including different organs and solid-associated, liquid-associated, and mucosal-associated locations, was selected for different bacterial communities due to environmental conditions and anatomical features specific to each location, that is, biogeography (97–99), even within the first few days of life (100). These IL-10-KO mice were raised in pathogen-free conditions and had acquired some gut microbiota prior to beginning the experiment. Adding a conventionally raised mouse to the IL-10-KO mouse cages, and moving the cages to a conventional mouse

room, stimulates additional microbial transmission (101) and allows IL-10-KO mice to acquire new gut microbiota even as they react negatively to them. However, IL-10-KO mice on a control diet displayed no biogeographic signal in the gut. It is possible that the inflammation damage to the epithelium or the lack of IL-10 may prevent a typical biogeographic signal from forming. Hypothetically, no biogeographic patterns of bacteria in the gut could indicate that the community is not functioning in a way that benefits the host.

The third experimental factor of this study, and the one that showed to be the least significant driver of microbial community dissimilarity, was the anatomical location of sample derivation. We found that the number of bacterial taxa (SVs) in the cecum and proximal colon of the younger trial 1 mice fed broccoli sprouts was significantly elevated, as compared to the control trial 1 mice, and significant community dissimilarity between the broccoli sprout diet group and the control group in both the cecum and the distal colon. There were no significant dietary treatment effects on richness or bacterial community similarity in any anatomical location studied in the older trial 2 mice (Fig. 4B). The cecum houses a diverse community of fibrolytic bacteria, with fiber in the ileocecal junction to be pulled into, allowing for more microbial fermentation (102, 103). Mice have a large cecum, even in IL-10-KO mice this organ acquires a diverse microbiota (72, 104). Studies on IBD models report significant inflammation and changes to cecal microbiota in mice (47, 105, 106). It is likely that given the short duration of this experimental period, the cecum and parts of the colon that also house diverse microbiota were the only organs that were suited to recruit differential bacterial communities fast enough to be statistically significant.

Raw broccoli sprouts encouraged some putatively beneficial taxa

The CD has specifically been associated with a reduction in *Faecalibacterium prausnitzii*, a putative GSL metabolizer, and the reintroduction of this bacteria resulted in decreased inflammation (107). However, many gut microorganisms are only useful to the host in specific metabolic conditions (108, 109), which can obfuscate our understanding of which microorganisms may be useful to try and maintain to preserve beneficial interactions with the host. Furthermore, commensalism cannot be assumed for any taxa, as IL-10-KO mice infected with *Helicobacter* also exhibited a higher abundance of non-commensal *Bacteroides* and *Lactobacillus* species (110).

SFN is bacteriostatic against taxa which may provide some benefit to mice, including *Bacteroides* (111), a genera containing known GSL metabolizers (69), and non-pathogenic *Bacillus* or *Enterococcus*. Across our experimental groups, we found several bacterial genera, including *Bacteroides* (but not *Bacteroides thetaiotaomicron*), *Enterococcus casseliflavus*, *Lactobacillus gasseri*, and others in very low abundance, that may perform myrosinase-like activity (68). *Enterococcus casseliflavus* are gram-positive, motile facultative anaerobes sourced from vegetables, with high GSL degradation efficiency (112). One SV was matched to *E. casseliflavus* based on BLASTN results in the older mice and favored the broccoli mice (1164 count) compared to the control (113 count). Although GLR was low in the broccoli diet (4 µg per gram of diet sampled), *E. casseliflavus* may have been responsible for some of the conversion to SFN. *Lactobacillus gasseri* was the most abundant species with putative myrosinase-like enzymatic activity. A probiotic strain with implications for fighting pathogens, *L. gasseri* has hydrolyzed GLR to SFN in the cecum of rats (39, 113). Four SVs were mapped to *L. gasseri* using BLASTN. These sequences were most abundant in the control for both trials, with the highest counts occurring in the younger control mice.

Contrary to expectations, except for *Bacteroides caecimuris*, *Enterococcus casseliflavus*, and *Lactobacillus intestinalis*, the species identified from GSL converting genera tended to be found in control treatments for both age groups of mice, although it is important to note that the use of 16S rDNA precluded any assessment of microbial activity. There was a greater abundance of putative GSL converting taxa associated with the older mice (7–9 weeks old), except in the cecum where the abundances were higher for the

younger mice. The high concentration of SFN in the diet, and low concentration of the GLR precursor, may have precluded the need for metabolizing competent bacteria, and it may be that the taxa present in younger mice were sensitive to the presence of SFN while the community present in older mice was not. By contrast, mice on the broccoli sprout diet overall demonstrated higher indications of the presence of the operon BT2159-BT2156, suggesting *B. theta* may be the primary GLR convertor in these mice, and suggesting that 16S rDNA taxonomic identification on its own may not be an accurate metric for presumptive GLR conversion in the gut. Using the presence of the operon as a metric, the use of a broccoli diet to recruit functional *B. theta* was most strongly indicated for young mice (4–6 weeks-old), supporting our *a posteriori* hypothesis.

Raw broccoli sprouts reduced putative proinflammatory bacteria

The causal relationship between potentially pathogenic bacteria and the onset of IBD symptoms remains murky (34, 114), with postulations about the involvement of various microorganisms, including *Mycobacterium avium* subspecies *paratuberculosis*, adherent-invasive *Escherichia coli*, *Mycoplasma* spp., *Helicobacter pylori*, and *Chlamydia* spp. However, the role of proinflammatory bacteria in exacerbating flare-ups is clear, and proinflammatory bacteria have been identified in and found to be more abundant in IBD patients as compared to healthy children (31) or adults (34), although often newly diagnosed children exhibit similar fecal microbial communities compared to healthy siblings (115).

SFN induces colonocytes to produce several antimicrobial compounds (116), something which is lacking in CD patients with abnormally functioning Paneth cells (117). SFN itself is bacteriostatic against several bacteria, including *Escherichia coli*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, *S. epidermidis*, *Enterococcus faecalis*, *Bacillus cereus*, and *Helicobacter* spp. (50, 51, 65). Interestingly, our results suggest that consumption of broccoli sprouts may prevent the accumulation of putatively harmful, pro-inflammatory bacteria. When compared to the controls, the broccoli-fed mice exhibited less prevalence and abundance of *Helicobacter*, which is a non-harmful commensal in conventionally raised and immune-competent mice (118) but acts as a pro-inflammatory bacterial genus in IL-10-KO mice (57). The specific species of *Helicobacter* which colonies IL-10-KO mice can also affect the host's immune response and severity of symptoms (119).

Whole food strategies provide multiple mechanisms of benefit and harm reduction

In many but not all people or circumstances, high-fiber diets increase microbial diversity, recruit beneficial species in the gut, and reduce inflammation by providing antioxidants or antimicrobials against microbial competitors (116, 120). Dietary fiber has the potential to reduce the risk of Crohn's flare-ups by up to 40% (121), and high-fiber foods can stimulate beneficial microbial byproducts in the gut (120). However, during a flare-up, high-fiber foods can worsen symptoms, and certain fiber types can exacerbate symptoms (122). Opting for foods rich in soluble fiber, which can help slow down digestion and ease diarrhea, is recommended for individuals with CD. On the other hand, foods containing insoluble fiber can increase water content in the gut, leading to rapid digestion, watery diarrhea, stomach cramps, or gas, and in severe cases, may cause blockages in patients with CD.

Using purified GLR or SFN has been evaluated as a means of inducing health benefits while avoiding fiber in IBD patients, with varying effectiveness (40, 53). Feeding SFN directly to mice does not appear to change cecal butyrate (123), and while butyrate treatments to the gut are often successful in patients with ulcerative colitis it is unclear whether butyrate is helpful for patients with CD as cellular damage may prevent colonocytes from utilizing it (124).

We balanced the 10% raw broccoli sprout/90% control diet to the 100% control diet by total fiber, and the control diet contains oats which are a prime source of microbially produced butyrate (125). While mature broccoli is a reliable source of fiber and stimulates butyrate production by gut bacteria, there is no literature to suggest that broccoli sprouts would stimulate more microbial fermentation and byproducts than the equivalent grams of fiber from oats. Furthermore, we found no putative butyrate-producing genera in our sprout-fed mice: no *Bifidobacterium*, *Clostridium*, or *Butyrococcus*, and *Bacteroides* were only high in the younger control mice. Similarly, *Bifidobacterium*, *Clostridium*, and *Bacteroides* can dissociate bile salts in the colon, which otherwise exacerbate symptoms in IBD patients, and we found *Lactobacillus intestinalis*, also capable of this (126), in our sprout-fed mice. Finally, the mucin-degrading capacity of gut bacteria is reduced in CD and UC patients (127), and alterations to the gut microbiota could have action here.

Although some studies have indicated positive outcomes with anti-inflammatory dietary interventions in children and adolescents with CD, their effectiveness may vary among individuals. Factors such as adherence to the prescribed diet, individual tolerance to specific foods, and the involvement of healthcare professionals in monitoring progress all play critical roles. Diet can also trigger symptoms of IBD, however; it is important to note that there is no singular food or food group that can be universally linked to every case of CD, as different individuals may experience gut irritation and inflammation from different foods. Children and adolescents with CD may exhibit distinct manifestations compared to adults, often presenting with more extensive disease involvement, including perianal disease and structural complications (31–33). Consequently, personalized recommendations are often needed, and the unique nutritional requirements of pediatric and adolescent populations must be addressed to ensure adequate nutrient intake for growth, development, and overall health (71).

Limitations and future directions

Due to the short duration of the experiment, we were unable to discern if the increase in diversity persists into adulthood, and if this would preclude the development of more intense symptoms and damage to the intestinal epithelium. We lacked sufficient power to determine sex-specific differences in response to diet (67, 128), immune function (129), and microbial acquisition (130). We also lacked data to determine microbial activity, beneficial or detrimental, due to short sequence lengths.

Future research will be required to examine the effect of cooking preparation on the concentrations of precursors and bioactives that are contained in the diet and available in the gut, as well as microbially sourced bioactives, and will require metabolomics to fully explore this. The myrosinase enzyme present in broccoli and sprouts can metabolize the GLR precursor to bioactive SFN when the plant tissues are cut or chewed, but the majority of the precursor is converted to biologically inactive SFN nitrile by the epithiospecifier protein, also present in broccoli (8). SFN was high in our raw sprout diet, which was an effect of the preparation process stimulating the release of myrosinase. However, SFN is an unstable molecule and will not persist unless kept frozen. These enzymes can be inactivated by cooking, preserving the stable precursor in the diet, and allowing gut microbiota to perform the conversion in the intestines (38).

Future research will be needed into the feasibility and adaptability of this intervention. The difficulty in managing CD symptoms is costly to patients (131), and healthcare systems (132, 133). Furthermore, many IBD patients may be told to avoid fiber for fear of exacerbating symptoms or aggravating tender intestines (18, 41). Given the importance of diet in supporting host health and microbiota, we underscore the need for understanding dietary preferences, and for incorporating nutritional intervention as part of a holistic treatment for gastrointestinal inflammation.

MATERIALS AND METHODS

Diet

Multiple lots of Jonathan's Sprouts (Rochester, MA, USA) broccoli sprouts were purchased from a nearby grocery store (Bangor, ME, USA) and stored in a -80°C freezer until freeze-drying at the University of Maine Pilot Plant (Orono, ME, USA) to lower moisture content and reduce enzymatic activity. The control diet was 100% irradiated 5LOD diet irradiated 5LOD rodent diet powder (ScottPharma Inc., Marlborough, MA, #50795) mixed with ultra-pure water. The freeze-dried sprouts were crushed by mortar and pestle into a fine powder and mixed with the 5LOD powder and water to a concentration of 10% by weight to form the treatment diet, as that concentration reliably produces consistent anti-inflammatory results (48). Diet pellets were formed using a silicone mold to ensure consistent sizing, dried at room temperature for up to 48 h in a chemical safety hood to facilitate moisture evaporation, and after drying were stored in Ziploc bags in a -10°C freezer until future use. The sprouts are washed prior to packaging, and freezing, freeze-drying, and drying reduce microbial biomass, growth, and activity, and may kill some bacteria through desiccation. However, we did not verify that diets were sterile after formulating them, as the goal of the experiment was to introduce microbiota to mice.

The fiber content of the control diet and broccoli sprout-supplemented diet was $\sim 5\%$. No GLR or SFN was found in the control and the sprout diet contained an average of $4\ \mu\text{g}$ of GLR and $85\ \mu\text{g}$ of SFN (induced when raw diets are crushed and myrosinase is released from broccoli tissue vesicles) per gram of dried diet sampled (Fig. S8), using LC/MS (38).

IL-10 mouse model

Two replicate trials were conducted using male and female IL-10-KO mice (*Mus musculus*) on a C57BL/6 background (B6.129P2-Il10tm1Cgn/J, strain 2251; Jackson Laboratories, Bar Harbor, ME, USA). IL-10-KO mice are a well-demonstrated model for Crohn's research and the C57BL/6 genetic line shows some genetic-based resistance to developing symptoms (55), which allowed us to focus on environmental triggers of the disease.

Trial 1 included 9 mice ($n = 4$, control; $n = 5$ sprout) starting at 4 weeks of age and post-weaning. Trial 2 included 11 mice ($n = 6$, control; $n = 5$ sprout) starting at 7 weeks of age. The experimental design was structured as a prevention paradigm (Fig. 1). A colony of homozygous IL-10-KO mice was maintained in a barrier facility that is specifically pathogen-free, and especially *Helicobacter* (*H.*) *hepaticus* free. For the duration of the trial, they were fed either the 5LOD control diet or the treatment diet consisting of 10% (wt/wt) raw broccoli sprouts and 90% control diet, which was balanced for micronutrients and fiber (5% of diet). Mice had access to tap water *ad libitum*.

Mice were acclimated to diets for 7 days prior to the induction of colitis, which was achieved by moving mice to a conventional mouse room and adding an *H. hepaticus*-positive mouse in the cage for the remainder of the experiment. The *H. hepaticus*-positive mouse transfers commensal bacteria, as well as species that may cause infection in immunocompromised mice, *via* feces and grooming, and bacteria induce colitis over the course of 10 days (55, 60). While *H. hepaticus* is widespread in research mouse colonies and causes disease in immunocompromised mice, it does not cause symptoms in healthy, conventional mice (118). The conventional mice were fed an irradiated RMH 3000 diet (Prolab IsoPro) prior to being co-housed with IL-10-KO mice, at which point they consumed the control or 10% broccoli sprout diets based on the cage treatment. Day 0 of each trial was set as the day the IL-10 mice were exposed to the *H. hepaticus* positive mouse, such that experimental day 10 is when symptoms appear (Fig. 1). Animals were euthanized by carbon dioxide and cervical dislocation on Day 16.

Assessment of disease activity index

Disease severity was assessed every other day beginning on day 0 when mice were co-housed with the *H. hepaticus*-positive mouse, using a DAI. This included a score

that combined fecal blood presence, severity, and stool consistency (134). The animals' weights were normalized to their baseline weight on day 0 of the trial, as at this age, mice are still in a growth phase and likely to gain weight even when under duress (135), and this was the rationale for excluding weight loss as part of the DAI criteria. The presence of fecal blood was assessed using Hemocult Single Slide testing slides (Beckman Coulter, Brea, CA, USA).

Assessment of lipocalin and proinflammatory cytokines

Plasma samples collected immediately after euthanasia, as well as fecal samples at various time points, were frozen for evaluation of fecal lipocalin (LCN2); a neutrophil protein that binds bacterial siderophores and serves as a biomarker for intestinal inflammation (64). Frozen fecal samples were weighed up to 20 mg and reconstituted in phosphate-buffered saline (PBS) with 0.2 mL of 0.1% Tween 20, thawed, and vortexed to create a homogeneous suspension. The samples were centrifuged for 10 min at 12,000 rpm at 4°C. Clear supernatant was collected and stored at -20°C until analysis. LCN2 concentration was measured by a mouse Lipocalin-2/NGAL DuoSet ELISA kit (R & D Biosystems, USA) following the manufacturer's instructions. The readings at wavelengths of 540 nm and 450 nm were measured by a Thermo Scientific Varioskan LUX Multimode Microplate Reader. The readings at 540 nm were subtracted from the readings at 450 nm to correct for the discoloration of the solution in serum.

We analyzed several pro-inflammatory cytokines in the mouse plasma samples which were collected at the end of the study: and IL-1 β , IL-6, and tumor necrosis factor alpha (TNF- α), which play several roles in regulating immune responses (136–138). The concentrations of mouse IL-1 β /IL1F2, IL6, and TNF- α were analyzed using the Simple Plex Ella Automated Immunoassay System (Ella) from R&D Biosystems, USA. Mouse serum samples were diluted 10-fold using the kit-specific reagent (SPCKA-MP-005977, Protein Simple, Bio-Techne), and the concentrations were measured following the manufacturer's instructions on the Ella system. Mean values were calculated for each cytokine and analyzed using ANOVA.

Quantification of plasma SFN

Plasma collected after euthanasia was also used for SFN measurement using LC/MS (38). To extract SFN, 50 μ L of plasma homogenate was mixed with 3-fold to 5-fold of acetonitrile and centrifuged at 14,000 rpm, 4°C for 15 min, and the supernatant stored at -20°C. An AB SCIEX QTRAP 4500 with a TurboV electrospray ionization source mass spectrometer (Applied Biosystems, Carlsbad, CA, USA) coupled to an Agilent 1200 Series HPLC system (Agilent Technologies, Santa Clara, CA, USA) was used for the quantification. HPLC separation was performed on a Waters XBridge C18 3.5 μ m 5 cm \times 2.1 mm column (Waters Corporation, Milford, MA, USA). Mobile phase A (water containing 0.1% formic acid) was first kept at 90% for 0.5 min and then decreased to 5% over 1 min and maintained at 5% for 2 min, and then returned to 10% mobile phase B (ACN containing 0.1% formic acid) and maintained for 3 min. The flow rate was 400 L/min. Positive ion MS/MS was conducted to detect SFN with the following conditions: source temperature, 400°C; curtain gas (CUR), 30 psi; ionspray voltage (IS), 4,500 V; desolvation gas temperature (TEM), 500°C; ion source gas 1 (GS1), 60 psi; ion source gas 2 (GS2), 40 psi; collision gas (CAD), high; entrance potential (EP), 4 eV; collision energy (CE), 15 eV. The MS/MS transition of 178 > 114 was used to detect SFN, and a dwell time of 50 ms was used for the transition. Data acquisition and quantitation were performed using Analyst software (Applied Biosystems, Carlsbad, CA).

Histological analysis of tissues

After euthanasia, tissue segments (1 cm, collected in duplicate) from the ileum, proximal colon, and distal colon were collected and fixed in 4% paraformaldehyde overnight for histological evaluation. Tissues were immediately rinsed with PBS, placed in 2%

paraformaldehyde/0.2% picric acid as a preservative, and stored at 4°C until transport to the University of Maine Electron Microscopy Laboratory (Orono, ME) for processing. All processing protocols took place in a biosafety cabinet using aseptic techniques to reduce contamination. A pipette was used to gently remove the previous PBS that the tissue was submerged in without disturbing the tissue while leaving a little bit of PBS behind to prevent the tissue from drying out. The sample tubes were refilled with fresh PBS, and the wash step was repeated four times throughout the day every 3 h with samples stored at 4°C between washes.

After the final wash step, the tissue samples were transferred into embedding baskets. The samples were dehydrated by immersing the samples in a graded series of ethanol at 4°C (50%, 70%, 80%, 95%, and 100% ethanol), cleared in xylene, and then infiltrated and finally embedded in Paraplast X-tra. During embedding, care was taken to orient the intestine samples to give a cross-section during sectioning. Slides were sectioned at 5 µm and stained in hematoxylin and eosin (139). Images were taken using an Olympus BX41 microscope with a Zeiss ERc 5s digital camera.

The tissues were scored with seven criteria (Fig. S1) used to assess inflammation in the ileum, and the proximal and distal colon tissues, performed according to the parameters provided by the Mawe Lab at the University of Vermont (140). Epithelial damage and architectural changes were scored from 0 (no damage) to 2 (extensive damage). Similarly, infiltration of mononuclear cells in the lamina propria was scored on a scale of 0 (no infiltration) to 2 (extensive infiltration). Infiltration of polymorphonuclear cells in both the lamina propria and the epithelium was scored on a scale of 0–2, with 0 indicating no infiltration, 1 equating to the sighting of ≥1 cell in each viewing field, and 2 equating to >3 cells in each viewing field. Abscesses, ulcers, erosion, and branched crypts were scored together with 0 being the absence of these damage indicators and 1 being the presence. Finally, the presence of granulomas was scored with 0 indicating no granulomas and 1 equating to ≥1 granulomas. Scores by treatment, anatomical location, and trial were compared with the analysis of variance.

DNA extraction and 16S rRNA bacterial sequencing library preparation

On day 16, following euthanasia, intestinal tissue segments (2 cm in length) were collected from the ileum, cecum, proximal colon, and distal colon; placed in RNAlater preservative (Invitrogen, Waltham, MA, USA); and transported overnight on ice to the University of Maine for DNA extraction. All DNA extraction processing steps took place in a biosafety cabinet using aseptic techniques to reduce contamination. All tissues containing their resident gut microbiota were gently homogenized with vortexing, and then treated with propidium monoazide (PMA; BioTium) following kit protocols at a final concentration of 25 µmol. PMA covalently binds to relic/free DNA and DNA inside compromised/dead cell membranes and prevents amplification in downstream protocols to preclude dead DNA from the sequence data.

Following PMA treatment, bulk DNA was extracted from tissue-associated bacterial communities ($n = 80$ samples) or no-template (water) control samples ($n = 4$, one for each extraction batch) using commercially available kits optimized for fecal-based microbial communities (Zymo fecal/soil kit), and some aliquots archived. DNA extract was roughly quantified and purity-checked with a Nanodrop spectrophotometer. Samples underwent DNA amplicon sequencing of the 16S rRNA gene V3-V4 region, using primers 341F (141) and 806R (142) and protocols consistent with The Earth Microbiome Project (143), and sequenced on an Illumina MiSeq platform using the 2 × 300-nt V3 kit (Molecular Research Labs, Clearwater, TX). Nine samples failed the first sequencing run and were extracted again for repeated sequencing.

16S rRNA bacterial community sequencing analysis

Amplicon sequence data were processed using previously curated workflows in the Ishaq Lab (Supplemental Material) which used the DADA2 pipeline ver. 1.22 (144) in the R software environment ver. 4.1.1 (145). The data set started with 38,287,212 million

raw reads from 80 samples and 4 negative controls. All samples were sequenced in an initial batch together, but five samples failed to meet all quality control standards and were resequenced. The two sequencing batches were put through quality control steps separately in DADA2 and combined before rarefaction. Trimming parameters were designated based on visual assessment of the aggregated quality scores at each base from all samples (plotQualityProfile in DADA2): the first and last 10 bases were trimmed, and sequences were discarded if they had ambiguous bases, more than two errors, or matching the PhiX version 3 positive control (Illumina; FC-110–3001). After filtering, 43,382,928 paired non-unique reads and 289 samples remained.

The DADA algorithm was used to estimate the error rates for the sequencing run, dereplicate the reads, pick SVs that represent “microbial individuals,” and remove chimeric artifacts from the sequence table. Taxonomy was assigned using the Silva taxonomic training data version 138.1 (146) and reads matching chloroplasts and mitochondria taxa were removed using the dplyr package (147). No-template control samples were used to remove contaminating sequences from the samples by extraction batch (148). The sequence table, taxonomy, and metadata were combined using the phyloseq package (149) to facilitate statistical analysis and visualization, representing 80 samples and 22,805 taxa. Due to the variability in sequences per sample which passed quality assurance parameters (range 12,060–157,040 sequences/sample), the data were rarefied (150, 151) to 12,060 sequences/sample.

Normality was checked using a Shapiro-Wilks test on alpha diversity metrics generated from rarefied data; observed richness ($W = 0.86662$, P -value = $1.186e-06$); evenness ($W = 0.89141$, P -value = $9.775e-06$); and Shannon diversity were not normally distributed ($W = 0.95012$, P -value = 0.005061). Linear models compared alpha diversity metrics (lme4 package (152)), in which anatomical location, diet treatment, and trial (either one or 2) were used as factors.

Jaccard unweighted similarity was used to calculate sample similarity based on community membership (species presence/absence), and non-parametric multidimensional scaling (trial 1 run 20 stress = 0.1940131 ; trial 2 run 20 stress = 0.1748438) and tested with permANOVA using the vegan package (153). Random forest feature prediction with permutation was used to identify differentially abundant SVs based on factorial conditions (154). Plots were made using the ggplot2 (155), ggpubr (156), and phyloseq packages. Source Tracker algorithms which had been modified for the R platform (157, 158) were used to identify source:sink effects based on anatomical location. This was used to determine whether the cecum could be the source for population sinks in the colon, as a proxy for the model's applicability to the human gut anatomical features and microbial communities (Fig. S6).

Quantitative PCR performed on genes that metabolize glucoraphanin

The ability of gut bacteria to perform glucoraphanin conversion to sulforaphane was assessed using gene sequences and primers associated with the established pathway in *Bacteroides thetaiotaomicron* VPI-5482 (69) (see Table S1). Gene sequences of interest from *B. thetaiotaomicron* VPI-5482 were evaluated through the ApE-A plasmid Editor v3.1.3 to confirm optimal melting temperature and GC content of primers, and assessment of primers was performed using NCBI primer blast (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/>) and IDT's OligoAnalyzer (www.idtdna.com). qPCR was completed on extracted DNA to determine copy numbers of glucoraphanin-metabolizing genes previously established in *B. thetaiotaomicron* using an Applied Biosystems QuantStudio 6 Flex Real-Time PCR system (Applied Biosystems, Foster City, CA, USA), primer sets BT2156-BT2160, and Luna Universal qPCR Master Mix were employed. After diluting primers to 10 μ M working concentration, the primer concentration in each well was 0.25 μ M. PCR conditions consisted of 1 cycle of 50°C for 2 min, 1 cycle of 95°C for 1 min, and 40 cycles of 95°C for 15 s, 60°C for 30 s and 72°C at 20, 25, or 30 s based on the primer set used (Table S1). Standard curves were generated for each gene by serially diluting geneblocks (IDT) six times. All standards and samples

were tested in triplicate, with standards and negative controls present on both plates. Using the standard curve produced in the Quantstudio analysis software, sample gene copy numbers were quantified. R software was used to run an analysis of variance, with corrections applied for multiple comparisons through Tukey's HSD.

ACKNOWLEDGMENTS

This project was supported by the USDA National Institute of Food and Agriculture through the Maine Agricultural & Forest Experiment Station: Hatch Project Numbers ME022102 and ME022329 (Ishaq) and ME022303 (Li); the USDA-NIFA-AFRI Foundational Program (Li and Chen; USDA/NIFA 2018-67017-27520/2018-67017-36797); and the National Institute of Health (Li and Ishaq; NIH/NIDDK 1R15DK133826-01) which supported Marissa Kinney, Timothy Hunt, and Benjamin Hunt. Johanna Holman was supported by ME0-22303 (Li), and Lola Holcomb was supported by the U.S. National Science Foundation One Health and the Environment (OG&E): Convergence of Social and Biological Sciences NRT program grant DGE-1922560, and the UMaine Graduate School of Biomedical Science and Engineering.

All authors have read and approved the final manuscript. Conceptualization, S.L.I., Y.L., T.Z., G.M.M., P.L.M., and G.C.; Methodology, S.L.I., Y.L., T.Z., G.M.M., P.L.M., J.M.H., L.M.H., M.H., B.L., and E.P.; Software, S.L.I.; Formal Analysis, J.M.H., L.M.H., S.L.I.; M.H., A.S., T.H., B.H., and M.K.; Investigation, M.H., B.L., J.M.H., L.H., L.C.; A.S., and J.P.; Resources, G.M.M., S.L.I., Y.L.; Data Curation, S.L.I., J.H., and L.H.; Writing—Original Draft, J.H., L.H., S.L.I., and Y.L.; Writing—Review and Editing; S.L.I., Y.L., T.Z., G.M.M., P.L.M., J.M.H., L.H., M.H., B.L., G.C., T.H., B.H., E.P., M.K., and J.P.; Visualization, J.H., L.H., S.L.I., A.S., T.H., B.H., and M.K.; Supervision, S.L.I., Y.L., T.Z.; and G.M.M.; Project Administration, S.L.I., Y.L., and G.M.M.; Funding Acquisition, S.L.I., Y.L., G.M.M., and G.C.

AUTHOR AFFILIATIONS

¹Graduate School of Biomedical Sciences and Engineering, University of Maine, Orono, Maine, USA

²School of Food and Agriculture, University of Maine, Orono, Maine, USA

³Larner College of Medicine, University of Vermont, Burlington, Vermont, USA

⁴Department of Biology, Husson University, Bangor, Maine, USA

⁵Department of Biology, University of Maine, Orono, Maine, USA

⁶Finch Therapeutics, Somerville, Massachusetts, USA

⁷Electron Microscopy Laboratory, University of Maine, Orono, Maine, USA

⁸School of Pharmacy and Pharmaceutical Sciences, SUNY Binghamton University, Johnson City, New York, USA

⁹Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA

AUTHOR ORCIDs

Suzanne L. Ishaq  <http://orcid.org/0000-0002-2615-8055>

Yanyan Li  <http://orcid.org/0000-0002-8139-6718>

FUNDING

Funder	Grant(s)	Author(s)
USDA National Institute of Food and Agriculture (NIFA)	ME022102, ME022329	Suzanne L. Ishaq
USDA National Institute of Food and Agriculture (NIFA)	ME022303	Yanyan Li
USDA National Institute of Food and Agriculture (NIFA)	2018-67017-27520, 2018-67017-36797	Grace Chen Yanyan Li

Funder	Grant(s)	Author(s)
HHS NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	1R15DK133826-01	Suzanne L. Ishaq Yanyan Li

AUTHOR CONTRIBUTIONS

Lola Holcomb, Formal analysis, Investigation, Methodology, Software, Visualization, Writing – original draft, Writing – review and editing | Johanna M. Holman, Formal analysis, Investigation, Methodology, Supervision, Visualization, Writing – original draft, Writing – review and editing | Molly Hurd, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing | Brigitte Lavoie, Formal analysis, Investigation, Supervision, Writing – original draft, Writing – review and editing | Louisa Colucci, Investigation, Writing – review and editing | Benjamin Hunt, Data curation, Formal analysis, Visualization, Writing – original draft, Writing – review and editing | Timothy Hunt, Data curation, Formal analysis, Visualization, Writing – original draft, Writing – review and editing | Marissa Kinney, Formal analysis, Investigation, Writing – review and editing | Jahnvi Pathak, Investigation, Writing – review and editing | Gary M. Mawe, Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing – review and editing | Peter L. Moses, Conceptualization, Writing – review and editing | Emma Perry, Methodology, Supervision, Writing – review and editing | Allesandra Stratigakis, Formal analysis, Visualization, Writing – review and editing | Tao Zhang, Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Supervision, Visualization, Writing – review and editing | Grace Chen, Conceptualization, Funding acquisition, Writing – review and editing | Suzanne L. Ishaq, Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Visualization, Writing – original draft, Writing – review and editing | Yanyan Li, Conceptualization, Funding acquisition, Methodology, Project administration, Supervision, Writing – original draft, Writing – review and editing

DATA AVAILABILITY

Raw sequence data (fastq files and metadata) from both sequencing runs are publicly available from the NCBI Sequence Read Archive (SRA) under BioProject accession no. [PRJNA909836](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA909836).

ETHICS APPROVAL

All experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of Vermont (PROTO202000040), in Burlington, VT, USA, and the Institutional Biosafety Committee of the University of Maine (protocol SI-092220).

ADDITIONAL FILES

The following material is available [online](#).

Supplemental Material

IL10 mouse R code (mSystems00688-23-S0001.txt). The R code that was used to clean, visualize, and statistically analyze the bacterial community sequencing data presented.

Supplemental figures and table (mSystems00688-23-S0002.pdf). Fig. S1 to S8 and Table S1.

REFERENCES

1. GBD 2016 DALYs and HALE Collaborators. 2017. Global, regional, and national disability-adjusted life-years (daly) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016. *Lancet* 390:1260–1344.
2. Sulz MC, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F, on behalf of the Swiss IBDnet, an official working group of the Swiss

- Society of Gastroenterology. 2020. Treatment algorithms for Crohn's disease. *Digestion* 101 Suppl 1:43–57. <https://doi.org/10.1159/000506364>
3. Lichtenstein GR, Shahabi A, Seabury SA, Lakdawalla DN, Espinosa OD, Green S, Brauer M, Baldassano RN. 2020. Lifetime economic burden of Crohn's disease and ulcerative colitis by age at diagnosis. *Clin Gastroenterol Hepatol* 18:889–897. <https://doi.org/10.1016/j.cgh.2019.07.022>
 4. Gao N, Qiao Z, Yan S, Zhu L. 2022. Evaluation of health-related quality of life and influencing factors in patients with Crohn disease. *J Int Med Res* 50:3000605221098868. <https://doi.org/10.1177/03000605221098868>
 5. Mitropoulou M-A, Fradelos EC, Lee KY, Malli F, Tsaras K, Christodoulou NG, Papatthanasiou IV. 2022. Quality of life in patients with inflammatory bowel disease: importance of psychological symptoms. *Cureus* 14:e28502. <https://doi.org/10.7759/cureus.28502>
 6. Hazel K, O'Connor A. 2020. Emerging treatments for inflammatory bowel disease. *Ther Adv Chronic Dis* 11:2040622319899297. <https://doi.org/10.1177/2040622319899297>
 7. Jiang Y, Wu S-H, Shu X-O, Xiang Y-B, Ji B-T, Milne GL, Cai Q, Zhang X, Gao Y-T, Zheng W, Yang G. 2014. Cruciferous vegetable intake is inversely correlated with circulating levels of proinflammatory markers in women. *J Acad Nutr Diet* 114:700–708. <https://doi.org/10.1016/j.jand.2013.12.019>
 8. Holman J, Hurd M, Moses PL, Mawe GM, Zhang T, Ishaq SL, Li Y. 2023. Interplay of broccoli/broccoli sprout Bioactives with gut microbiota in reducing inflammation in inflammatory bowel diseases. *J Nutr Biochem* 113:109238. <https://doi.org/10.1016/j.jnutbio.2022.109238>
 9. Gibbons SM, Kearney SM, Smillie CS, Alm EJ. 2017. Two dynamic regimes in the human gut microbiome. *PLoS Comput Biol* 13:e1005364. <https://doi.org/10.1371/journal.pcbi.1005364>
 10. Derrien M, Alvarez A-S, de Vos WM. 2019. The gut microbiota in the first decade of life. *Trends Microbiol* 27:997–1010. <https://doi.org/10.1016/j.tim.2019.08.001>
 11. Ostrem Loss E, Thompson J, Cheung PLK, Qian Y, Venturelli OS. 2023. Carbohydrate complexity limits microbial growth and reduces the sensitivity of human gut communities to perturbations. *Nat Ecol Evol* 7:127–142. <https://doi.org/10.1038/s41559-022-01930-9>
 12. Swidsinski A, Ladhoff A, Perntaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. 2002. Mucosal flora in inflammatory bowel disease. *Gastroenterology* 122:44–54. <https://doi.org/10.1053/gast.2002.30294>
 13. Duvallet C, Gibbons SM, Gurry T, Irizarry RA, Alm EJ. 2017. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. *Nat Commun* 8:1784. <https://doi.org/10.1038/s41467-017-01973-8>
 14. Shalou D, Culver RN, Grembi JA, Folz J, Treit PV, Shi H, Rosenberger FA, Dethlefsen L, Meng X, Yaffe E, Aranda-Diaz A, Geyer PE, Mueller-Reif JB, Spencer S, Patterson AD, Triadafilopoulos G, Holmes SP, Mann M, Fiehn O, Relman DA, Huang KC. 2023. Profiling the human intestinal environment under physiological conditions. *Nature* 617:581–591. <https://doi.org/10.1038/s41586-023-05989-7>
 15. Khan I, Bai Y, Ullah N, Liu G, Rajoka MSR, Zhang C, Yu J. 2022. Differential susceptibility of the gut microbiota to DSS treatment interferes in the conserved microbiome association in Mouse models of colitis and is related to the initial gut microbiota difference. *Advanced Gut & Microbiome Research* 2022:1–20. <https://doi.org/10.1155/2022/7813278>
 16. Leshem A, Segal E, Elinav E. 2020. The gut microbiome and individual-specific responses to diet. *mSystems* 5:e00665-20. <https://doi.org/10.1128/mSystems.00665-20>
 17. Gibbons SM, Gurry T, Lampe JW, Chakrabarti A, Dam V, Everard A, Goas A, Gross G, Kleerebezem M, Lane J, Maukonen J, Penna ALB, Pot B, Valdes AM, Walton G, Weiss A, Zanzler YC, Venlet NV, Miani M. 2022. Perspective: leveraging the gut microbiota to predict personalized responses to dietary, prebiotic, and probiotic interventions. *Adv Nutr* 13:1450–1461. <https://doi.org/10.1093/advances/nmac075>
 18. Lewis JD, Abreu MT. 2017. Diet as a trigger or therapy for inflammatory bowel diseases. *Gastroenterology* 152:398–414. <https://doi.org/10.1053/j.gastro.2016.10.019>
 19. Limdi JK. 2018. Dietary practices and inflammatory bowel disease. *Indian J Gastroenterol* 37:284–292. <https://doi.org/10.1007/s12664-018-0890-5>
 20. Segal AW. 2019. Studies on patients establish Crohn's disease as a manifestation of impaired innate immunity. *J Intern Med* 286:373–388. <https://doi.org/10.1111/joim.12945>
 21. Gutiérrez A, Scharl M, Sempere L, Holler E, Zapater P, Almenta I, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R. 2014. Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. *Gut* 63:272–280. <https://doi.org/10.1136/gutjnl-2012-303557>
 22. Buisine MP, Desreumaux P, Debailleul V, Gambiez L, Geboes K, Ectors N, Delescaut MP, Degand P, Aubert JP, Colombel JF, Porchet N. 1999. Abnormalities in mucin gene expression in Crohn's disease. *Inflamm Bowel Dis* 5:24–32. <https://doi.org/10.1097/00054725-199902000-00004>
 23. Söderholm JD, Olaison G, Peterson KH, Franzén LE, Lindmark T, Wirén M, Tagesson C, Sjö Dahl R. 2002. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. *Gut* 50:307–313. <https://doi.org/10.1136/gut.50.3.307>
 24. Farrugia A, Arasaradnam R. 2021. Bile acid diarrhoea: pathophysiology, diagnosis and management. *Frontline Gastroenterol* 12:500–507. <https://doi.org/10.1136/flgastro-2020-101436>
 25. Eckburg PB, Relman DA. 2007. The role of microbes in Crohn's disease. *Clin Infect Dis* 44:256–262. <https://doi.org/10.1086/510385>
 26. Opiari A, Franchi L. 2015. Role of Inflammasomes in intestinal inflammation and Crohn's disease. *Inflamm Bowel Dis* 21:173–181. <https://doi.org/10.1097/MIB.0000000000000230>
 27. Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. 2020. Crohn's disease. *Nat Rev Dis Primers* 6:22. <https://doi.org/10.1038/s41572-020-0156-2>
 28. Weaver CT, Hatton RD. 2009. Interplay between the Th17 and Treg cell lineages: a (Co-)evolutionary perspective. *Nat Rev Immunol* 9:883–889. <https://doi.org/10.1038/nri2660>
 29. Nieminen U, Jussila A, Nordling S, Mustonen H, Färkkilä MA. 2014. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on Registry data. *Int J Cancer* 134:189–196. <https://doi.org/10.1002/ijc.28346>
 30. Lindoso L, Mondal K, Venkateswaran S, Somineni HK, Ballengee C, Walters TD, Griffiths A, Noe JD, Crandall W, Snapper S, Rabizadeh S, Rosh JR, LeLeiko N, Guthery S, Mack D, Kellermayer R, Gulati AS, Pfefferkorn MD, Moulton DE, Keljo D, Cohen S, Oliva-Hemker M, Heyman MB, Otley A, Baker SS, Evans JS, Kirschner BS, Patel AS, Ziring D, Stephens MC, Baldassano R, Dubinsky MC, Markowitz J, Denson LA, Hyams J, Kugathasan S, Ananthakrishnan AN. 2018. The effect of early-life environmental exposures on disease phenotype and clinical course of Crohn's disease in children. *Am J Gastroenterol* 113:1524–1529. <https://doi.org/10.1038/s41395-018-0239-9>
 31. Kaakoush NO, Day AS, Huinao KD, Leach ST, Lemberg DA, Dowd SE, Mitchell HM. 2012. Microbial dysbiosis in pediatric patients with Crohn's disease. *J Clin Microbiol* 50:3258–3266. <https://doi.org/10.1128/JCM.01396-12>
 32. Zhuang X, Liu C, Zhan S, Tian Z, Li N, Mao R, Zeng Z, Chen M. 2021. Gut microbiota profile in pediatric patients with inflammatory bowel disease: a systematic review. *Front Pediatr* 9:626232. <https://doi.org/10.3389/fped.2021.626232>
 33. Kowalska-Duplaga K, Gosiewski T, Kapusta P, Sroka-Oleksiak A, Wędrychowicz A, Pieczarkowski S, Ludwig-Słomczyńska AH, Wołkow PP, Fyderek K. 2019. Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn's disease. *Sci Rep* 9:18880. <https://doi.org/10.1038/s41598-019-55290-9>
 34. Wright EK, Kamm MA, Teo SM, Inouye M, Wagner J, Kirkwood CD. 2015. Recent advances in characterizing the gastrointestinal microbiome in Crohn's disease: a systematic review. *Inflamm Bowel Dis* 21:1219–1228. <https://doi.org/10.1097/MIB.0000000000000382>
 35. Chiodini RJ, Dowd SE, Chamberlin WM, Galandiuik S, Davis B, Glassing A. 2015. Microbial population differentials between mucosal and submucosal intestinal tissues in advanced Crohn's disease of the ileum. *PLoS One* 10:e0134382. <https://doi.org/10.1371/journal.pone.0134382>

36. Pascal V, Pozuelo M, Borrueal N, Casellas F, Campos D, Santiago A, Martinez X, Varela E, Sarrabayrouse G, Machiels K, Vermeire S, Sokol H, Guarner F, Manichanh C. 2017. A microbial signature for Crohn's disease. *Gut* 66:813–822. <https://doi.org/10.1136/gutjnl-2016-313235>
37. Ghazi LJ. 2023. Crohn disease. *Medscape* 172940
38. Zhang T, Holman J, McKinstry D, Trindade BC, Eaton KA, Mendoza-Castrejon J, Ho S, Wells E, Yuan H, Wen B, Sun D, Chen GY, Li Y. 2023. A steamed broccoli sprout diet preparation that reduces colitis via the gut microbiota. *J Nutr Biochem* 112:109215. <https://doi.org/10.1016/j.jnutbio.2022.109215>
39. Narbad A, Rossiter JT. 2018. Gut Glucosinolate metabolism and Isothiocyanate production. *Mol Nutr Food Res* 62:e1700991. <https://doi.org/10.1002/mnfr.201700991>
40. Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P. 2001. Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and excretion in humans. *Cancer Epidemiol Biomarkers Prev* 10:501–508.
41. Hou JK, Lee D, Lewis J. 2014. Diet and inflammatory bowel disease: review of patient-targeted recommendations. *Clin Gastroenterol Hepatol* 12:1592–1600. <https://doi.org/10.1016/j.cgh.2013.09.063>
42. Walker A, Schmitt-Kopplin P. 2021. The role of fecal sulfur metabolome in inflammatory bowel diseases. *Int J Med Microbiol* 311:151513. <https://doi.org/10.1016/j.ijmm.2021.151513>
43. Wei L-Y, Zhang J-K, Zheng L, Chen Y. 2022. The functional role of sulforaphane in intestinal inflammation: a review. *Food Funct* 13:514–529. <https://doi.org/10.1039/d1fo03398k>
44. Mueller K, Blum NM, Mueller AS. 2013. Examination of the anti-inflammatory, antioxidant, and xenobiotic-inducing potential of broccoli extract and various essential oils during a mild DSS-induced colitis in rats. *ISRN Gastroenterol* 2013:710856. <https://doi.org/10.1155/2013/710856>
45. Liu T, Zhang L, Joo D, Sun S-C. 2017. NF-KB signaling in inflammation. *Signal Transduct Target Ther* 2:17023 <https://doi.org/10.1038/sigtrans.2017.23>
46. Burnett JP, Lim G, Li Y, Shah RB, Lim R, Paholak HJ, McDermott SP, Sun L, Tsume Y, Bai S, Wicha MS, Sun D, Zhang T. 2017. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells. *Cancer Lett* 394:52–64. <https://doi.org/10.1016/j.canlet.2017.02.023>
47. Holman JM, Colucci L, Baudewyns D, Balkan J, Hunt T, Hunt B, Kinney M, Holcomb L, Stratigakis A, Chen G, Moses PL, Mawe GM, Zhang T, Li Y, Ishaq SL, Manichanh C. 2023. Steamed broccoli sprouts alleviate DSS-induced inflammation and retain gut microbial biogeography in mice. *mSystems*. <https://doi.org/10.1128/msystems.00532-23>
48. Li Y, Zhang T, Holman J, McKinstry D, Trindade BC, Mendoza-Castrejon J, Ho S, Sun D, Wells E, Chen G. 2022. A specific broccoli sprout preparation reduces chemically-induced colitis via gut microbiota. *Curr Dev Nutr* 6:307. <https://doi.org/10.1093/cdn/nzac053.048>
49. Zhang Y, Tan L, Li C, Wu H, Ran D, Zhang Z. 2020. Sulforaphane alter the microbiota and mitigate colitis severity on mice ulcerative colitis induced by DSS. *AMB Expr* 10:119. <https://doi.org/10.1186/s13568-020-01053-z>
50. Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Talalay P, Lozniewski A. 2002. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of *Helicobacter pylori* and prevents benzo[a]pyrene-induced stomach tumors. *Proc Natl Acad Sci U S A* 99:7610–7615. <https://doi.org/10.1073/pnas.112203099>
51. Abukhabta S, Khalil Ghawi S, Karatzas KA, Charalampopoulos D, McDougall G, Allwood JW, Verrall S, Lavery S, Latimer C, Pourshahidi LK, Lawther R, O'Connor G, Rowland I, Gill CIR. 2021. Sulforaphane-enriched extracts from glucoraphanin-rich broccoli exert antimicrobial activity against gut pathogens *in vitro* and innovative cooking methods increase *in vivo* intestinal delivery of sulforaphane. *Eur J Nutr* 60:1263–1276. <https://doi.org/10.1007/s00394-020-02322-0>
52. Yuanfeng W, Chengzhi L, Ligen Z, Juan S, Xinjie S, Yao Z, Jianwei M. 2021. Approaches for enhancing the stability and formation of sulforaphane. *Food Chem* 345:128771. <https://doi.org/10.1016/j.foodchem.2020.128771>
53. Yagishita Y, Fahey JW, Dinkova-Kostova AT, Kensler TW. 2019. Broccoli or Sulforaphane: is it the source or dose that matters *Molecules* 24:3593. <https://doi.org/10.3390/molecules24193593>
54. Rennick DM, Fort MM. 2000. XII. IL-10-deficient (IL-10^{-/-}) mice and intestinal inflammation. *Am J Physiol Gastrointest Liver Physiol* 278:G829–G833. <https://doi.org/10.1152/ajpgi.2000.278.6.G829>
55. Keubler LM, Buettner M, Häger C, Bleich A. 2015. A multihit model: colitis lessons from the interleukin-10-deficient mouse. *Inflamm Bowel Dis* 21:1967–1975. <https://doi.org/10.1097/MIB.0000000000000468>
56. Glocker E-O, Kotlarz D, Klein C, Shah N, Grimbacher B. 2011. IL-10 and IL-10 receptor defects in humans. *Ann N Y Acad Sci* 1246:102–107. <https://doi.org/10.1111/j.1749-6632.2011.06339.x>
57. Burich A, Hershberg R, Waggie K, Zeng W, Brabb T, Westrich G, Viney JL, Maggio-Price L. 2001. Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice. *Am J Physiol Gastrointest Liver Physiol* 281:G764–78. <https://doi.org/10.1152/ajpgi.2001.281.3.G764>
58. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell* 75:263–274. [https://doi.org/10.1016/0092-8674\(93\)80068-p](https://doi.org/10.1016/0092-8674(93)80068-p)
59. Kennedy RJ, Hoper M, Deodhar K, Erwin PJ, Kirk SJ, Gardiner KR. 2000. Interleukin 10-deficient colitis: new similarities to human inflammatory bowel disease. *Br J Surg* 87:1346–1351. <https://doi.org/10.1046/j.1365-2168.2000.01615.x>
60. Mähler M, Leiter EH. 2002. Genetic and environmental context determines the course of colitis developing in IL-10-deficient mice. *Inflamm Bowel Dis* 8:347–355. <https://doi.org/10.1097/00054725-200209000-00006>
61. Knoop KA, Gustafsson JK, McDonald KG, Kulkarni DH, Coughlin PE, McCrate S, Kim D, Hsieh C-S, Hogan SP, Elson CO, Tarr PI, Newberry RD. 2017. Microbial antigen encounter during a preweaning interval is critical for tolerance to gut bacteria. *Sci Immunol* 2:eaa01314. <https://doi.org/10.1126/sciimmunol.aao1314>
62. Stewart CJ, Ajami NJ, O'Brien JL, Hutchinson DS, Smith DP, Wong MC, Ross MC, Lloyd RE, Doddapaneni H, Metcalf GA, Muzny D, Gibbs RA, Vatanen T, Huttenhower C, Xavier RJ, Rewers M, Hagopian W, Toppari J, Ziegler A-G, She J-X, Akolkar B, Lernmark A, Hyoty H, Vehik K, Krischer JP, Petrosino JF. 2018. Temporal development of the gut microbiome in early childhood from the TEDDY study. *Nature* 562:583–588. <https://doi.org/10.1038/s41586-018-0617-x>
63. Fahey JW, Zhang Y, Talalay P. 1997. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. *Proc Natl Acad Sci U S A* 94:10367–10372. <https://doi.org/10.1073/pnas.94.19.10367>
64. Chassaing B, Srinivasan G, Delgado MA, Young AN, Gewirtz AT, Vijay-Kumar M. 2012. Fecal Lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. *PLoS One* 7:e44328. <https://doi.org/10.1371/journal.pone.0044328>
65. Nowicki D, Maciąg-Dorszyńska M, Bogucka K, Szalewska-Pałasz A, Herman-Antosiewicz A. 2019. Various modes of action of dietary phytochemicals, sulforaphane and phenethyl isothiocyanate, on pathogenic bacteria. *Sci Rep* 9:13677. <https://doi.org/10.1038/s41598-019-50216-x>
66. Wang D, Jin H, Sheng J, Cheng L, Lin Q, Lazerev M, Jin P, Li X. 2022. A high salt diet protects interleukin 10-deficient mice against chronic colitis by improving the mucosal barrier function. *Mol Immunol* 150:39–46. <https://doi.org/10.1016/j.molimm.2022.07.010>
67. Zhang Z, Hyun JE, Thiesen A, Park H, Hotte N, Watanabe H, Higashiyama T, Madsen KL. 2020. Sex-specific differences in the gut microbiome in response to dietary fiber supplementation in IL-10-deficient mice. *Nutrients* 12:2088. <https://doi.org/10.3390/nu12072088>
68. Sikorska-Zimny K, Beneduce L. 2021. The metabolism of glucosinolates by gut microbiota. *Nutrients* 13:2750. <https://doi.org/10.3390/nu13082750>
69. Liou CS, Sirk SJ, Diaz CAC, Klein AP, Fischer CR, Higginbottom SK, Erez A, Donia MS, Sonnenburg JL, Sattely ES. 2020. A metabolic pathway for activation of dietary glucosinolates by a human gut symbiont. *Cell* 180:717–728. <https://doi.org/10.1016/j.cell.2020.01.023>
70. Baumgart DC, Sandborn WJ. 2012. Crohn's disease. *Lancet* 380:1590–1605. [https://doi.org/10.1016/S0140-6736\(12\)60026-9](https://doi.org/10.1016/S0140-6736(12)60026-9)
71. Hansen T, Duerksen DR. 2018. Enteral nutrition in the management of pediatric and adult Crohn's disease. *Nutrients* 10:537. <https://doi.org/10.3390/nu10050537>

72. Knoch B, Nones K, Barnett MPG, McNabb WC, Roy NC. 2010. Diversity of caecal bacteria is altered in Interleukin-10 gene-deficient mice before and after colitis onset and when fed polyunsaturated fatty acids. *Microbiology (Reading)* 156:3306–3316. <https://doi.org/10.1099/mic.0.041723-0>
73. Overstreet A-M, Ramer-Tait AE, Suchodolski JS, Hostetter JM, Wang C, Jergens AE, Phillips GJ, Wannemuehler MJ. 2020. Temporal dynamics of chronic inflammation on the cecal microbiota in IL-10^{-/-} mice. *Front Immunol* 11:585431. <https://doi.org/10.3389/fimmu.2020.585431>
74. Berding K, Holscher HD, Arthur AE, Donovan SM. 2018. Fecal microbiome composition and stability in 4- to 8-year old children is associated with dietary patterns and nutrient intake. *J Nutr Biochem* 56:165–174. <https://doi.org/10.1016/j.jnutbio.2018.01.002>
75. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto J-M, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker J-D, Raes J, Hansen T, MetaHIT consortium, Bork P, Wang J, Ehrlich SD, Pedersen O. 2013. Richness of human gut microbiome correlates with metabolic markers. *Nature* 500:541–546. <https://doi.org/10.1038/nature12506>
76. Park JH, Kwon JG, Kim SJ, Song DK, Lee SG, Kim ES, Cho KB, Jang BI, Kim DH, Sin J-I, Kim TW, Song IH, Park KS. 2015. Alterations of colonic contractility in an interleukin-10 knockout mouse model of inflammatory bowel disease. *J Neurogastroenterol Motil* 21:51–61. <https://doi.org/10.5056/jnm14008>
77. Cohen SL, Moore AM, Ward WE. 2004. Interleukin-10 knockout mouse: a model for studying bone metabolism during intestinal inflammation. *Inflamm Bowel Dis* 10:557–563.
78. Veeranki OL, Bhattacharya A, Marshall JR, Zhang Y. 2013. Organ-specific exposure and response to sulforaphane, a key chemopreventive ingredient in broccoli: implications for cancer prevention. *Br J Nutr* 109:25–32. <https://doi.org/10.1017/S0007114512000657>
79. Eichele DD, Kharbanda KK. 2017. Dextran sodium sulfate colitis murine model: an indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. *World J Gastroenterol* 23:6016–6029. <https://doi.org/10.3748/wjg.v23.i33.6016>
80. Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, Neurath MF. 2017. Chemically induced mouse models of acute and chronic intestinal inflammation. *Nat Protoc* 12:1295–1309. <https://doi.org/10.1038/nprot.2017.044>
81. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. 1990. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. *Gastroenterology* 98:694–702. [https://doi.org/10.1016/0016-5085\(90\)90290-h](https://doi.org/10.1016/0016-5085(90)90290-h)
82. Poritz LS, Garver KI, Green C, Fitzpatrick L, Ruggiero F, Koltun WA. 2007. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. *J Surg Res* 140:12–19. <https://doi.org/10.1016/j.jss.2006.07.050>
83. Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M. 2014. Dextran sulfate sodium (DSS)-Induced colitis in mice. *Curr Protoc Immunol* 104:15. <https://doi.org/10.1002/0471142735.im1525s104>
84. Araki A, Kanai T, Ishikura T, Makita S, Uraushihara K, Iiyama R, Totsuka T, Takeda K, Akira S, Watanabe M. 2005. Myd88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. *J Gastroenterol* 40:16–23. <https://doi.org/10.1007/s00535-004-1492-9>
85. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. 1994. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. *Gastroenterology* 107:1643–1652. [https://doi.org/10.1016/0016-5085\(94\)90803-6](https://doi.org/10.1016/0016-5085(94)90803-6)
86. Bhattacharyya S, Dudeja PK, Tobacman JK. 2009. ROS, Hsp27, and Ikkbeta mediate dextran sodium sulfate (DSS) activation of IkappaB, NFkappaB, and IL-8. *Inflamm Bowel Dis* 15:673–683. <https://doi.org/10.1002/ibd.20821>
87. Yang Y, Jia H, Lyu W, Furukawa K, Li X, Hasebe Y, Kato H. 2022. Dietary eggshell membrane powder improves survival rate and ameliorates gut dysbiosis in interleukin-10 knockout mice. *Front Nutr* 9:895665. <https://doi.org/10.3389/fnut.2022.895665>
88. Kondo H, Abe I, Gotoh K, Fukui A, Takanari H, Ishii Y, Ikebe Y, Kira S, Oniki T, Saito S, Aoki K, Tanino T, Mitarai K, Kawano K, Miyoshi M, Fujinami M, Yoshimura S, Ayabe R, Okada N, Nagano Y, Akioka H, Shinohara T, Akiyoshi K, Masaki T, Teshima Y, Yufu K, Nakagawa M, Takahashi N. 2018. Interleukin 10 treatment ameliorates high-fat diet-induced inflammatory atrial remodeling and fibrillation. *Circ Arrhythm Electrophysiol* 11:e006040. <https://doi.org/10.1161/CIRCEP.117.006040>
89. Kowalski GM, Nicholls HT, Risis S, Watson NK, Kanellakis P, Bruce CR, Bobik A, Lancaster GI, Febbraio MA. 2011. Deficiency of haematopoietic-cell-derived IL-10 does not exacerbate high-fat-diet-induced inflammation or insulin resistance in mice. *Diabetologia* 54:888–899. <https://doi.org/10.1007/s00125-010-2020-5>
90. Martínez I, Maldonado-Gomez MX, Gomes-Neto JC, Kittana H, Ding H, Schmalz R, Joglekar P, Cardona RJ, Marsteller NL, Kembel SW, Benson AK, Peterson DA, Ramer-Tait AE, Walter J. 2018. Experimental evaluation of the importance of colonization history in early-life gut microbiota assembly. *Elife* 7:e36521. <https://doi.org/10.7554/eLife.36521>
91. Kemp KM, Colson J, Lorenz RG, Maynard CL, Pollock JS. 2021. Early life stress in mice alters gut microbiota independent of maternal microbiota inheritance. *Am J Physiol Regul Integr Comp Physiol* 320:R663–R674. <https://doi.org/10.1152/ajpregu.00072.2020>
92. Knoop KA, McDonald KG, Coughlin PE, Kulkarni DH, Gustafsson JK, Rusconi B, John V, Ndao IM, Beigelman A, Good M, Warner BB, Elson CO, Hsieh C-S, Hogan SP, Tarr PI, Newberry RD. 2020. Synchronization of mothers and offspring promotes tolerance and limits allergy. *JCI Insight* 5:e137943. <https://doi.org/10.1172/jci.insight.137943>
93. Schloss PD, Schubert AM, Zackular JP, Iverson KD, Young VB, Petrosino JF. 2012. Stabilization of the murine gut microbiome following weaning. *Gut Microbes* 3:383–393. <https://doi.org/10.4161/gmic.21008>
94. Delage C, Taib T, Mamma C, Lerouet D, Besson VC. 2021. Traumatic brain injury: an age-dependent view of post-traumatic neuroinflammation and its treatment. *Pharmaceutics* 13:1624. <https://doi.org/10.3390/pharmaceutics13101624>
95. Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, Li Y, Xia Y, Xie H, Zhong H, Khan MT, Zhang J, Li J, Xiao L, Al-Aama J, Zhang D, Lee YS, Kotowska D, Colding C, Tremaroli V, Yin Y, Bergman S, Xu X, Madsen L, Kristiansen K, Dahlgren J, Wang J. 2015. Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell Host Microbe* 17:852. <https://doi.org/10.1016/j.chom.2015.05.012>
96. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, Clemente JC, Knight R, Heath AC, Leibel RL, Rosenbaum M, Gordon JI. 2013. The long-term stability of the human gut microbiota. *Science* 341:1237439. <https://doi.org/10.1126/science.1237439>
97. Tropini C, Earle KA, Huang KC, Sonnenburg JL. 2017. The gut microbiome: connecting spatial organization to function. *Cell Host Microbe* 21:433–442. <https://doi.org/10.1016/j.chom.2017.03.010>
98. Kadriu H, Yeoman C. 2022. The unseen minority: biogeographical investigations of the ruminant gastrointestinal microbiome highlight the importance of frequently ignored anatomical regions, p. 179–191. In Kogut, MH, Zhang, G (eds.), *Gut microbiota, immunity, and health in production animals*. Springer International Publishing, Cham, Switzerland.
99. Suzuki TA, Nachman MW. 2016. Spatial heterogeneity of gut microbial composition along the gastrointestinal tract in natural populations of house mice. *PLoS One* 11:e0163720. <https://doi.org/10.1371/journal.pone.0163720>
100. Yeoman CJ, Ishaq SL, Bichi E, Olivo SK, Lowe J, Aldridge BM. 2018. Biogeographical differences in the influence of maternal microbial sources on the early successional development of the bovine neonatal gastrointestinal tract. *Sci Rep* 8:3197. <https://doi.org/10.1038/s41598-018-21440-8>
101. Hildebrand F, Nguyen TLA, Brinkman B, Yunta RG, Cauwe B, Vandenaabeele P, Liston A, Raes J. 2013. Inflammation-associated enterotypes, host genotype, cage and inter-individual effects drive gut microbiota variation in common laboratory mice. *Genome Biol* 14:R4. <https://doi.org/10.1186/gb-2013-14-1-r4>
102. Snipes RL. 1981. Anatomy of the cecum of the laboratory mouse and rat. *Anat Embryol* 162:455–474. <https://doi.org/10.1007/BF00301871>
103. Gordon JH, Dubos R. 1970. The anaerobic bacterial flora of the mouse cecum. *J Exp Med* 132:251–260. <https://doi.org/10.1084/jem.132.2.251>
104. Boger-May A, Reed T, LaTorre D, Ruley-Haase K, Hoffman H, English L, Roncagli C, Overstreet A-M, Boone D. 2022. Altered microbial

- biogeography in an innate model of colitis. *Gut Microbes* 14:2123677. <https://doi.org/10.1080/19490976.2022.2123677>
105. Kozik AJ, Nakatsu K, Chun H, Jones-Hall YL. 2019. Comparison of the fecal, cecal, and cecum microbiome in male and female mice after TNBS-induced colitis. *PLoS One* 14:e0225079. <https://doi.org/10.1371/journal.pone.0225079>
 106. Hubbard TD, Murray IA, Nichols RG, Cassel K, Podolsky M, Kuzu G, Tian Y, Smith P, Kennett MJ, Patterson AD, Perdew GH. 2017. Dietary broccoli impacts microbial community structure and attenuates chemically induced colitis in mice in an Ah receptor dependent manner. *J Funct Foods* 37:685–698. <https://doi.org/10.1016/j.jff.2017.08.038>
 107. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux J-J, Blugeon S, Bridonneau C, Furet J-P, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. 2008. *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proc Natl Acad Sci U S A* 105:16731–16736. <https://doi.org/10.1073/pnas.0804812105>
 108. Ridlon JM, Devendran S, Alves JM, Doden H, Wolf PG, Pereira GV, Ly L, Volland A, Takei H, Nittono H, Murai T, Kurosawa T, Chlipala GE, Green SJ, Hernandez AG, Fields CJ, Wright CL, Kakiyama G, Cann I, Kashyap P, McCracken V, Gaskins HR. 2020. “The *in vivo* lifestyle” of bile acid 7 α -dehydroxylating bacteria: comparative genomics, metatranscriptomic, and bile acid metabolomics analysis of a defined microbial community in gnotobiotic mice. *Gut Microbes* 11:381–404. <https://doi.org/10.1080/19490976.2019.1618173>
 109. Sonnenburg JL, Xu J, Leip DD, Chen C-H, Westover BP, Weatherford J, Buhler JD, Gordon JI. 2005. Glycan foraging *in vivo* by an intestine-adapted bacterial symbiont. *Science* 307:1955–1959. <https://doi.org/10.1126/science.1109051>
 110. Büchler G, Wos-Oxley ML, Smoczek A, Zschemisch N-H, Neumann D, Pieper DH, Hedrich HJ, Bleich A. 2012. Strain-specific colitis susceptibility in IL10-deficient mice depends on complex gut microbiota-host interactions. *Inflamm Bowel Dis* 18:943–954. <https://doi.org/10.1002/ibd.21895>
 111. Wang R, Halimulati M, Huang X, Ma Y, Li L, Zhang Z. 2023. Sulfaphane-driven reprogramming of gut microbiome and metabolome ameliorates the progression of hyperuricemia. *J Adv Res* 52:19–28. <https://doi.org/10.1016/j.jare.2022.11.003>
 112. Luang-In V, Albaser AA, Nueno-Palop C, Bennett MH, Nabad A, Rossiter JT. 2016. Glucosinolate and desulfo-glucosinolate metabolism by a selection of human gut bacteria. *Curr Microbiol* 73:442–451. <https://doi.org/10.1007/s00284-016-1079-8>
 113. Laiz L, Miller AZ, Jurado V, Akatova E, Sanchez-Moral S, Gonzalez JM, Dionísio A, Macedo MF, Saiz-Jimenez C. 2009. Isolation of five *Rubrobacter* strains from biodeteriorated monuments. *Naturwissenschaften* 96:71–79. <https://doi.org/10.1007/s00114-008-0452-2>
 114. Axelrad JE, Cadwell KH, Colombel J-F, Shah SC. 2021. The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review. *Therap Adv Gastroenterol* 14:17562848211004493. <https://doi.org/10.1177/17562848211004493>
 115. Hedin CR, McCarthy NE, Louis P, Farquharson FM, McCartney S, Taylor K, Prescott NJ, Murrells T, Stagg AJ, Whelan K, Lindsay JO. 2014. Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn’s disease and their unaffected siblings. *Gut* 63:1578–1586. <https://doi.org/10.1136/gutjnl-2013-306226>
 116. Schwab M, Reyniers D, Loitsch S, Steinhilber D, Schröder O, Stein J. 2008. The dietary histone deacetylase inhibitor sulforaphane induces human beta-defensin-2 in intestinal epithelial cells. *Immunology* 125:241–251. <https://doi.org/10.1111/j.1365-2567.2008.02834.x>
 117. Liu T-C, Gurram B, Baldrige MT, Head R, Lam V, Luo C, Cao Y, Simpson P, Hayward M, Holtz ML, Bousounis P, Noe J, Lerner D, Cabrera J, Biank V, Stephens M, Huttenhower C, McGovern DPB, Xavier RJ, Stappenbeck TS, Salzman NH. 2016. Paneth cell defects in Crohn’s disease patients promote dysbiosis. *JCI Insight* 1:e86907. <https://doi.org/10.1172/jci.insight.86907>
 118. Ericsson AC, Franklin CL. 2021. The gut microbiome of laboratory mice: considerations and best practices for translational research. *Mamm Genome* 32:239–250. <https://doi.org/10.1007/s00335-021-09863-7>
 119. Chichlowski M, Sharp JM, Vanderford DA, Myles MH, Hale LP. 2008. *Helicobacter typhlonius* and *Helicobacter rodentium* differentially affect the severity of colon inflammation and inflammation-associated neoplasia in IL10-deficient mice. *Comp Med* 58:534–541.
 120. Makki K, Deehan EC, Walter J, Bäckhed F. 2018. The impact of dietary fiber on gut microbiota in host health and disease. *Cell Host Microbe* 23:705–715. <https://doi.org/10.1016/j.chom.2018.05.012>
 121. Brotherton CS, Martin CA, Long MD, Kappelman MD, Sandler RS. 2016. Avoidance of fiber is associated with greater risk of Crohn’s disease flare in a 6-month period. *Clin Gastroenterol Hepatol* 14:1130–1136. <https://doi.org/10.1016/j.cgh.2015.12.029>
 122. Armstrong HK, Bording-Jorgensen M, Santer DM, Zhang Z, Valcheva R, Rieger AM, Sung-Ho Kim J, Dijk SI, Mahmood R, Ogungbola O, Jovel J, Moreau F, Gorman H, Dickner R, Jerasi J, Mander IK, Lafleur D, Cheng C, Petrova A, Jeanson T-L, Mason A, Sergi CM, Levine A, Chadee K, Armstrong D, Rauscher S, Bernstein CN, Carroll MW, Huynh HQ, Walter J, Madsen KL, Dieleman LA, Wine E. 2023. Unfermented β -fructan fibers fuel inflammation in select inflammatory bowel disease patients. *Gastroenterology* 164:228–240. <https://doi.org/10.1053/j.gastro.2022.09.034>
 123. He C, Huang L, Lei P, Liu X, Li B, Shan Y. 2018. Sulforaphane normalizes intestinal flora and enhances gut barrier in mice with BBN-induced bladder cancer. *Mol Nutr Food Res* 62:e1800427. <https://doi.org/10.1002/mnfr.201800427>
 124. Hodgkinson K, El Abbar F, Dobranowski P, Manoogian J, Butcher J, Figeys D, Mack D, Stintzi A. 2023. Butyrate’s role in human health and the current progress towards its clinical application to treat gastrointestinal disease. *Clin Nutr* 42:61–75. <https://doi.org/10.1016/j.clnu.2022.10.024>
 125. Hallert C, Björck I, Nyman M, Pousette A, Grännö C, Svensson H. 2003. Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. *Inflamm Bowel Dis* 9:116–121. <https://doi.org/10.1097/00054725-200303000-00005>
 126. O’Flaherty S, Briner Crawley A, Theriot CM, Barrangou R. 2018. The lactobacillus bile salt hydrolase repertoire reveals niche-specific adaptation. *mSphere* 3:e00140-18. <https://doi.org/10.1128/mSphere.00140-18>
 127. Włodarska M, Luo C, Kolde R, d’Hennezel E, Annand JW, Heim CE, Krastel P, Schmitt EK, Omar AS, Creasey EA, Garner AL, Mohammadi S, O’Connell DJ, Abubucker S, Arthur TD, Franzosa EA, Huttenhower C, Murphy LO, Haiser HJ, Vlamakis H, Porter JA, Xavier RJ. 2017. Indoleacrylic acid produced by commensal peptostreptococcus species suppresses inflammation. *Cell Host Microbe* 22:25–37. <https://doi.org/10.1016/j.chom.2017.06.007>
 128. Seifert HA, Gerstner G, Kent G, Vandenbark AA, Offner H. 2019. Estrogen-induced compensatory mechanisms protect IL-10-deficient mice from developing EAE. *J Neuroinflammation* 16:195. <https://doi.org/10.1186/s12974-019-1588-z>
 129. Bábíčková J, Tóthová L, Lengyelová E, Bartoňová A, Hodosy J, Gardlík R, Celec P. 2015. Sex differences in experimentally induced colitis in mice: a role for estrogens. *Inflammation* 38:1996–2006. <https://doi.org/10.1007/s10753-015-0180-7>
 130. Jašarević E, Howerton KL, Howard CD, Bale TL. 2015. Alterations in the vaginal microbiome by maternal stress are associated with metabolic reprogramming of the offspring gut and brain. *Endocrinology* 156:3265–3276. <https://doi.org/10.1210/en.2015-1177>
 131. Park KT, Ehrlich OG, Allen JI, Meadows P, Szigethy EM, Henrichsen K, Kim SC, Lawton RC, Murphy SM, Regueiro M, Rubin DT, Engel-Nitz NM, Heller CA. 2020. The cost of inflammatory bowel disease: an initiative from the Crohn’s & colitis foundation. *Inflamm Bowel Dis* 26:1–10. <https://doi.org/10.1093/ibd/izaa081>
 132. Singh S, Qian AS, Nguyen NH, Ho SKM, Luo J, Jairath V, Sandborn WJ, Ma C. 2022. Trends in U.S. health care spending on inflammatory bowel diseases, 1996–2016. *Inflamm Bowel Dis* 28:364–372. <https://doi.org/10.1093/ibd/izab074>
 133. Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL, Jensen ET, Shaheen NJ, Barritt AS, Lieber SR, Kochar B, Barnes EL, Fan YC, Pate V, Galanko J, Baron TH, Sandler RS. 2019. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. *Gastroenterology* 156:254–272. <https://doi.org/10.1053/j.gastro.2018.08.063>
 134. Dieleman LA, Peña AS, Meuwissen SG, van Rees EP. 1997. Role of animal models for the pathogenesis and treatment of inflammatory bowel disease. *Scand J Gastroenterol Suppl* 223:99–104.
 135. Roy N, Barnett M, Knoch B, Dommels Y, McNabb W. 2007. Nutrigenomics applied to an animal model of inflammatory bowel diseases: transcriptomic analysis of the effects of eicosapentaenoic acid- and

- arachidonic acid-enriched diets. *Mutat Res* 622:103–116. <https://doi.org/10.1016/j.mrfmmm.2007.04.003>
136. Yu W, Li Q, Shao C, Zhang Y, Kang C, Zheng Y, Liu X, Liu X, Yan J. 2022. The Cao-Xiang-wei-Kang formula attenuates the progression of experimental colitis by restoring the homeostasis of the microbiome and suppressing inflammation. *Front Pharmacol* 13:946065. <https://doi.org/10.3389/fphar.2022.946065>
 137. Prakash T, Janadri S. 2023. Anti-inflammatory effect of wedelolactone on DSS induced colitis in rats: IL-6/Stat3 signaling pathway. *J Ayurveda Integr Med* 14:100544. <https://doi.org/10.1016/j.jaim.2022.100544>
 138. Gobert AP, Al-Greene NT, Singh K, Coburn LA, Sierra JC, Verriere TG, Luis PB, Schneider C, Asim M, Allaman MM, Barry DP, Cleveland JL, Destefano Shields CE, Casero RA, Washington MK, Piazuelo MB, Wilson KT. 2018. Distinct immunomodulatory effects of spermine oxidase in colitis induced by epithelial injury or infection. *Front Immunol* 9:1242. <https://doi.org/10.3389/fimmu.2018.01242>
 139. Cardiff RD, Miller CH, Munn RJ. 2014. Manual hematoxylin and eosin staining of mouse tissue sections. *Cold Spring Harb Protoc* 2014:655–658. <https://doi.org/10.1101/pdb.prot073411>
 140. Spohn SN, Bianco F, Scott RB, Keenan CM, Linton AA, O'Neill CH, Bonora E, Dickey M, Lavoie B, Wilcox RL, MacNaughton WK, De Giorgio R, Sharkey KA, Mawe GM. 2016. Protective actions of epithelial 5-hydroxytryptamine 4 receptors in normal and inflamed colon. *Gastroenterology* 151:933–944. <https://doi.org/10.1053/j.gastro.2016.07.032>
 141. Fadrosch DW, Ma B, Gajer P, Sengamalay N, Ott S, Brotman RM, Ravel J. 2014. An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform. *Microbiome* 2:6. <https://doi.org/10.1186/2049-2618-2-6>
 142. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, Fierer N, Knight R. 2011. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. *Proc Natl Acad Sci U S A* 108 Suppl 1:4516–4522. <https://doi.org/10.1073/pnas.100080107>
 143. The earth Microbiome project. 2011. The earth microbiome project. <http://www.earthmicrobiome.org>.
 144. Callahan B. 2022. DADA2: fast and accurate sample inference from amplicon data with single-nucleotide resolution (1.16). Available from: <https://benjjneb.github.io/dada2/tutorial.html>
 145. RCoreTeam. 2022. R: a language and environment for statistical computing (4.2.2). R foundation for statistical computing, Vienna, Austria. Available from: <https://www.r-project.org>
 146. Pruesse E, Quast C, Knittel K, Fuchs BM, Ludwig W, Peplies J, Glöckner FO. 2007. SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. *Nucleic Acids Res* 35:7188–7196. <https://doi.org/10.1093/nar/gkm864>
 147. Wickham H, Francois R, Henry L, Müller K. 2015. dplyr: a grammar of data manipulation. R package version 0.4.3. R found stat comput, vienna. Available from: <https://CRAN.R-project.org/package=dplyr>
 148. Ishaq SL. 2017. Github. *Phyloseq_dealing_with_neg_controls_Ishaq_example.R*. Github. Available from: <https://github.com/Suelshaq/Examples-DADA2-Phyloseq>. Retrieved 5 Mar 2019.
 149. McMurdie PJ, Holmes S, Watson M. 2013. Phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. *PLoS ONE* 8:e61217. <https://doi.org/10.1371/journal.pone.0061217>
 150. Weiss S, Xu ZZ, Peddada S, Amir A, Bittinger K, Gonzalez A, Lozupone C, Zaneveld JR, Vázquez-Baeza Y, Birmingham A, Hyde ER, Knight R. 2017. Normalization and microbial differential abundance strategies depend upon data characteristics. *Microbiome* 5:27. <https://doi.org/10.1186/s40168-017-0237-y>
 151. Cameron ES, Schmidt PJ, Tremblay B-M, Emelko MB, Müller KM. 2021. Enhancing diversity analysis by repeatedly rarefying next generation sequencing data describing microbial communities. *Sci Rep* 11:22302. <https://doi.org/10.1038/s41598-021-01636-1>
 152. Bates D, Mächler M, Zurich E, Bolker BM, Walker SC. 2015. Fitting linear mixed-effects models using lme4. *J Stat Softw* 67:1–48. <https://doi.org/10.18637/jss.v067.i01>
 153. Oksanen J, Guillaume Blanchet F, Friendly M, Kindt R, Legendre P, McGlenn D, Minchin PR, O'Hara RB, Simpson GL, Solymos P, Stevens MHH, Szoecs E, Wagner H. 2020. Vegan: community ecology package (2.5-7). Available from: <https://cran.r-project.org/web/packages/vegan/vignettes/diversity-vegan.pdf>
 154. Archer E. 2022. rfpermute: estimate permutation *P*-values for random forest importance metrics (2.5.1). Available from: <https://github.com/EricArcher/rfPermute>
 155. Wickham H. 2016. ggplot2: elegant graphics for data analysis. Springer Publishing Company, New York. Available from: <https://dl.acm.org/citation.cfm?id=1795559>.
 156. Kassambara A. 2022. ggpubr: “ggplot2” based publication ready plots (0.1.7). Available from: <https://rpkgs.datanovia.com/ggpubr>
 157. Knights D, Kuczynski J, Charlson ES, Zaneveld J, Mozer MC, Collman RG, Bushman FD, Knight R, Kelley ST. 2011. Bayesian community-wide culture-independent microbial source tracking. *Nat Methods* 8:761–763. <https://doi.org/10.1038/nmeth.1650>
 158. Galey M. 2021. Mi-Seq analysis. GitHub. Available from: <https://mgaley-004.github.io/MiSeq-Analysis/Tutorials/SourceSink.html>, <https://github.com/mgaley-004/MiSeq-Analysis>. Retrieved 7 Dec 2022.